Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 47
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Tesis doctoral (DoctoralThesis)

Cryo Eco-systems virology. A systems biology approach to the study of Cryosphere viral communities

  • Sánchez Carrillo, Sergio
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología Molecular. Fecha de Lectura: 09-09-2025, Esta Tesis tiene embargado el acceso al texto completo hasta el 09-03-2027, La Criosfera, aunque dominada por el hielo, alberga comunidades microbianas diversas y activas donde los virus juegan un papel clave. Regulan poblaciones, movilizan nutrientes mediante el "viral shunt" y genes metabólicos auxiliares (AMGs), aunque su función ecológica sigue poco explorada. Esta tesis adopta un enfoque de Biología de Sistemas centrado en virus, aplicado a tres ecosistemas modelo. En suelos antárticos, se identificaron virus dominados por fagos líticos y se hallaron nuevas familias virales asociadas a factores ambientales como la altitud o la distancia al mar. En una cueva alpina de hielo fósil, los viromas mostraron señales de adaptación prolongada al frío y posibles movilizaciones de virus antiguos por el deshielo. Finalmente, en lagos criosféricos de distintas regiones, se evidenció una fuerte estratificación viral asociada a los gradientes de profundidad, así como una estructura comunitaria influida por la dispersión limitada y las condiciones locales. En conjunto, los virus de la Criosfera resultan altamente novedosos, estructurados por gradientes ambientales y mayoritariamente líticos. Sus AMGs fortalecen rutas metabólicas clave, como las del azufre, y el deshielo podría liberar virus antiguos con impactos aún desconocidos. Esta tesis propone el marco conceptual Cryo Eco-Systems Virology para avanzar en la comprensión del papel viral en ambientes fríos ante el cambio climático, This work has been carried out thanks to funding obtained through the following grants: 1) Formación del Profesorado Universitario (FPU18/04695), 2) Viral and microbial diversity in the Ordesa and Monte Perdido National Park: sensor of climate change (BBVA Foundation; PR[19]ECO0047; PI: A.Alcamí), 3) Ancient viruses and microorganisms in polar lakes (PID10643 POLARPALEOVIRUS; EU Horizon 2020, EASIGenomics; PI: A. Alcamí), and 4) Diversity o fDNA and RNA viruses in Antarctica (No. 505820; Contract No DE-AC02-05CH11231; Joint Genome Institute, U.S. Department of Energy; PI: A.Alcamí).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2

  • DeDiego, Marta L.|||0000-0002-7888-7372
  • López-Fernández-Sobrino, Raúl
  • Pedragosa, Jordi|||0000-0001-8493-4545
  • López-García, Darío
  • Nogales, Aitor
  • Durbán, Jordi
  • Cardona, Fernando
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Rivero, Vanessa
  • Vazquez-Utrilla, Paula
  • Palomo Sanchez-Grande, Laura
  • Cobo, Miriam
  • Lloret, Lara
  • Márquez-Kisinousky, Leonardo
  • Ruiz-Jaén, Francisca
  • Lozano, Francisco
  • Sibila, Oriol|||0000-0002-4833-6713
  • Faner, Rosa|||0000-0002-8159-0115
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Domingo, Carlos
  • Robles, Verónica
  • Bedini, Josep L.
  • Rico, Verónica
  • Aguero, Daiana
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Martínez, Alba Parra
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Serra-Llovich, Alexandre|||0000-0001-8318-851X
  • Dietl, Beatriz|||0000-0001-6011-6986
  • Arranz, M. Jesús
  • Dalmau, David|||0000-0003-1936-478X
  • Signes-Costa, Jaime
  • Gil-Carbonell, Joan
  • Todolí, José
  • Martínez, Jacobo
  • Rojo, Silvia
  • Fiz-López, Aida
  • Arribas, Elisa
  • Cal-Sabater, Paloma
  • Bernado, David
  • Vogel, Marina
  • Wiemann, Stefan|||0000-0003-4683-3174
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Pan-Hammarström, Qiang|||0000-0003-1990-8804
  • Pujol, Aurora|||0000-0002-9606-0600
  • Su, Helen C.|||0000-0002-5582-9110
  • Lee, Danyel|||0000-0003-3124-0245
  • Zhang, Shen-Ying|||0000-0002-9449-3672
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Planas, Anna Maria|||0000-0002-6147-1880
Recessive deficiency in 2',5'-oligoadenylate synthetase (OAS) or RNase L can cause systemic inflammation in children with SARS-CoV-2 infection, but its role in adult respiratory disease is unclear. We analyzed rare OAS1/OAS3 variants and the common OAS1 rs10774671 polymorphism in 342 COVID-19 patients, assessing enzymatic activity, RNase L activation, viral replication, and inflammation in cell systems and Oas3-deficient mice. Rare heterozygous variants showed impaired RNase L activation but were not enriched in pneumonia cases. In contrast, the rs10774671 A/A genotype (OAS1-p42 isoform) was associated with severe disease (OR = 2.28; 95% CI = 1.13-4.58; p = 0.0107) and reduced viral control despite intact RNase L activation. OAS3 and OAS1-p46 isoform limited viral replication and inflammatory responses, whereas Oas3-deficient mice showed increased cytokines. These findings suggest that common OAS1 variation influences COVID-19 severity, while rare OAS variants may affect inflammation regulation rather than respiratory pathology.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

  • Asano, Takaki
  • Gut, Marta
  • Casanova, Jean-Laurent
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10-5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4 We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7 The patients' blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract., Funding: The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, Rockefeller University; the St. Giles Foundation; the NIH (R01AI088364), the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866); a Fast Grant from Emergent Ventures; Mercatus Center at the George Mason University; the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956); the Meyer Foundation; the JPB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01) and the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (EQU201903007798); the FRM and ANR GENCOVID project, the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AABIFNCOV (ANR-20-CO11-0001) projects; the European Union’s Horizon 2020 Research and Innovation Program under grant agreement no. 824110 (EASI-genomics). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). The Neurometabolic Diseases Laboratory received funding from the European Union’s Horizon 2020 Research and Innovation Program (EasiGenomics grant no. 824110 COVID-19/PID12342). A.P., R.P.d.D., C.R.-G., and C.F. were funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación DISA (OA18/017), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The laboratories of G.N. and A.N. were supported by a grant awarded to Regione Lazio (PROGETTI DI GRUPPI DI RICERCA 2020) no. A0375-2020-36663, GecoBiomark. A. Amara’s laboratory was supported by ANR under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the FRM (EQU202003010193), ANR (ANR-20-COVI-000 project IDISCOVR and ANR-20-CO11-0004 project FISHBP), and the University of Paris (Plan de Soutien Covid-19: RACPL20FIR01-COVID-SOUL). This work was supported, in part, by the Division of Intramural Research, NIAID, NIH (grants 1ZIAAI001265 to H.C.S. and ZIA AI001270 to L.D.N.). The G.C. laboratory was supported by the Italian Ministry of Health (grant COVID-2020-12371617) and the intramural COVID Host Genetics program. The J.L.F. laboratory was supported, in part, by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX; 806-2018) and Colciencias contract 713-2016 (no. 111574455633). The V.S. laboratory was supported by ANR DENDRISEPSIS (ANR-17-CE15-0003) and ANR APCOD (ANR-17-CE15-0003-01), a Fast Grant from the Mercatus Center, FRM, University of Paris PLAN D’URGENCE COVID19. The N.M. laboratory was supported by Sidra Medicine (SDR400048) and the Qatar National Research Fund (grant No. NPRP9-251-3-045)
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Combining nanopore and illumina sequencing permits detailed analysis of insertion mutations and structural variations produced by PEG-Mediated transformation in ostreococcus tauri

  • Thomy, Julie
  • Sanchez, Frederic
  • Gut, Marta
  • Cruz, Fernando
  • Alioto, Tyler
  • Piganeau, Gwenael
  • Grimsley, Nigel
  • Yau, Sheree
Ostreococcus tauri is a simple unicellular green alga representing an ecologically important group of phytoplankton in oceans worldwide. Modern molecular techniques must be developed in order to understand the mechanisms that permit adaptation of microalgae to their environment. We present for the first time in O. tauri a detailed characterization of individual genomic integration events of foreign DNA of plasmid origin after PEG-mediated transformation. Vector integration occurred randomly at a single locus in the genome and mainly as a single copy. Thus, we confirmed the utility of this technique for insertional mutagenesis. While the mechanism of double-stranded DNA repair in the O. tauri model remains to be elucidated, we clearly demonstrate by genome resequencing that the integration of the vector leads to frequent structural variations (deletions/insertions and duplications) and some chromosomal rearrangements in the genome at the insertion loci. Furthermore, we often observed variations in the vector sequence itself. From these observations, we speculate that a nonhomologous end-joining-like mechanism is employed during random insertion events, as described in plants and other freshwater algal models. PEG-mediated transformation is therefore a promising molecular biology tool, not only for functional genomic studies, but also for biotechnological research in this ecologically important marine alga., This research received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 824110—EASI-Genomics and the French National Research Agency project grant (ANR Algalvirus ANR-17-CE02-0012). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and cofinancing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D&apos;Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children

  • Lee, Danyel
  • COVID Human Genetic Effort
  • Zhang, Shen-Ying
Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition that follows benign COVID-19. We report autosomal recessive deficiencies of OAS1, OAS2, or RNASEL in five unrelated children with MIS-C. The cytosolic double-stranded RNA (dsRNA)-sensing OAS1 and OAS2 generate 2'-5'-linked oligoadenylates (2-5A) that activate the single-stranded RNA-degrading ribonuclease L (RNase L). Monocytic cell lines and primary myeloid cells with OAS1, OAS2, or RNase L deficiencies produce excessive amounts of inflammatory cytokines upon dsRNA or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stimulation. Exogenous 2-5A suppresses cytokine production in OAS1-deficient but not RNase L-deficient cells. Cytokine production in RNase L-deficient cells is impaired by MDA5 or RIG-I deficiency and abolished by mitochondrial antiviral-signaling protein (MAVS) deficiency. Recessive OAS-RNase L deficiencies in these patients unleash the production of SARS-CoV-2-triggered, MAVS-mediated inflammatory cytokines by mononuclear phagocytes, thereby underlying MIS-C., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R21AI160576), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High-Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU Program ANR-21-RHUS-08 (COVIFERON), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), and Paris Cité University. We acknowledge support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH under award R01AI104887 to R.H.S. and S.R.W. The Laboratory of Human Evolutionary Genetics (Institut Pasteur) is supported by the Institut Pasteur, the Collège de France, the French Government’s Investissement d’Avenir program, Laboratoires d’Excellence “Integrative Biology of Emerging Infectious Diseases” (ANR-10-LABX-62-IBEID) and “Milieu Intérieur” (ANR-10-LABX-69-01), the Fondation de France (no. 00106080), the FRM (Equipe FRM DEQ20180339214 team), and the ANR COVID-19-POPCELL (ANR-21-CO14-0003-01). A.Puj. is supported by ACCI20-759 CIBERER, EasiGenomics H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021-ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. The Canarian Health System sequencing hub was funded by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación MAPFRE Guanarteme (OA21/131), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The CoV-Contact Cohort was funded by the French Ministry of Health and the European Commission (RECOVER project). Our studies are also funded by the Ministry of Health of the Czech Republic Conceptual Development of Research Organization (FNBr, 65269705) and ANID COVID0999 funding in Chile. G. Novelli and A. Novelli are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark. A.M.P., M.L.D., and J.P.-T. are supported by the Inmungen-CoV2 project of CSIC. This work was supported in part by the Intramural Research Program of the NIAID, NIH. The research work of A.M..P, M.L.D., and J.P.-T. was funded by the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). I.M. is a senior clinical investigator at FWO Vlaanderen supported by a VIB GC PID grant, by FWO grants G0B5120N (DADA2) and G0E8420N, and by the Jeffrey Modell Foundation. I.M. holds an ERC-StG MORE2ADA2 grant and is also supported by ERN-RITA.​ A.Y. is supported by fellowships from the European Academy of Dermatology and Venereology and the Swiss National Science Foundation and by an Early Career Award from the Thrasher Research Fund. Y.-H.C. is supported by an A*STAR International Fellowship (AIF). M.O. was supported by the David Rockefeller Graduate Program, the New York Hideyo Noguchi Memorial Society (HNMS), the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the National Cancer Institute (NCI) F99 Award (F99CA274708). A.A.A. was supported by Ministerio de Ciencia Tecnología e Innovación MINCIENCIAS, Colombia (111584467551/CT 415-2020). D.L. is supported by a fellowship from the FRM for medical residents and fellows. E.H. received funding from the Bank of Montreal Chair of Pediatric Immunology, Foundation of CHU Sainte-Justine, CIHR grants PCC-466901 and MM1-181123, and a Canadian Pediatric Society IMPACT study. Q.P.-H. received funding from the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650), the Swedish Research Council, and the Knut and Alice Wallenberg Foundation. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, and R01AI161444; a George Mason University Fast Grant; the G. Harold and Leila Y. Mathers Charitable Foundation; the Meyer Foundation; and the Bawd Foundation. R.P.L. is on the board of directors of both Roche and the Roche subsidiary Genentech. J.L.P. was supported by a Francois Wallace Monahan Postdoctoral Fellowship at the Rockefeller University and by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Inborn errors of type I IFN immunity in patients

  • Zhang, Qian
  • Gut, Marta
  • Casanova, Jean-Laurent
Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection., This work was supported by a generous donation from the Fisher Center for Alzheimer’s Research Foundation. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the NIH (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project, ANRS-COV05, the Square Foundation, Grandir–Fonds de Solidarité pour l’Enfance, the SCOR Corporate Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM), the University of Paris. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”), and the Intramural Research Program of the NIAID, NIH. The laboratory of Genomes & Cell Biology of Disease is supported by “Integrative Biology of Emerging Infectious Diseases” (grant no. ANR-10-LABX-62-IBEID), the “Fondation pour la Recherche Medicale” (grant FRM–EQU202003010193), the “Agence Nationale de la Recherche” (ANR FLASH COVID project IDISCOVR cofounded by the “Fondation pour la Recherche Médicale”), University of Paris (“Plan de Soutien Covid-19”: RACPL20FIR01-COVID-SOUL). I.M. is a senior clinical investigator with the FWO Vlaanderen; I.M. and L.M. are supported by FWO G0C8517N – GOB5120N. The VS team was supported by “Agence Nationale de la Recherche” (ANR-17-CE15-0003, ANR-17-CE15-0003-01) and by Université de Paris “PLAN D’URGENCE COVID19”. L.K. was supported by a fellowship from the French Ministry of Research. V.S.-S. is supported by a UKRI Future Leaders Fellowship (MR/S032304/1). S.Z.A.-M. is supported by the Elite Journals Program at King Saud University through grant no. PEJP-16-107. The J.M. laboratory is supported by Columbia University COVID biobank and grant no. UL1TR001873. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1; a George Mason University Fast Grant; and the G. Harold and Leila Y. Mathers Charitable Foundation. J.L.P. is supported by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018). Work at the Neurometabolic Diseases Laboratory received funding from the European Union’s Horizon 2020 research and innovation program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342) to A.P., and Roche and Illumina Covid Match Funds to M.G.. C.R.G. and colleagues are supported by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), Spanish Ministry of Science and Innovation, with the funding of European Regional Development Fund-European Social Fund -FEDER-FSE; (RTC-2017-6471-1; AEI/FEDER, UE), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). D.C.V. is supported by the Fonds de la recherche en santé du Québec clinician-scientist scholar program. H.S. is adjunct faculty at the University of Pennsylvania. A.-L.N. was supported by the Foundation Bettencourt Schueller. The Amsterdam UMC Covid-19 Biobank was funded by the Netherlands Organization for Health Research and Development (ZonMw, NWO-vici 91819627), The Corona Research Fund (Amsterdam UMC), Dr. J. C. Vaillantfonds, and Amsterdam UMC. Work on COVID-19 at the A.G.-S. laboratory is partly supported by NIH supplements to grants U19AI135972, U19AI142733, and R35 HL135834, and to contract HHSN272201800048C, by a DoD supplement to grant W81XWH-20-1-0270, by DARPA project HR0011-19-2-0020, by CRIP (Center for Research on Influenza Pathogenesis), a NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract HHSN272201400008C), by an NIAID funded Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC, contract 75N93019C00051) and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611(5384)) and anonymous donors. The Virscan analysis presented in fig. S11 was performed with financial support from Sidra Medicine. J.R.H. is supported by Biomedical Advanced Research and Development Authority under Contract (HHSO10201600031C).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths

  • Bastard, Paul
  • Gut, Marta
  • Casanova, Jean-Laurent
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS Nord-Sud (ANRS-COV05), ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-genomics), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM) and the University of Paris. PB was supported by the French Foundation for Medical Research (FRM, EA20170638020). PB, JR and TLV were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). Work in the Laboratory of Virology and Infectious Disease was supported by the NIH (P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1), a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). This work was also partly supported by the Intramural Research Program of the NIAID and NIDCR, NIH (grants ZIA AI001270 to LDN and 1ZIAAI001265 to HCS). This program is supported by the Agence Nationale de la Recherche, reference ANR-10-LABX-69-01. K. Kisand’s group was supported by the Estonian Research Council grant PRG117 and PRG377. R. Halwani is supported by a grant from Al Jalila Foundation Seed Grant (AJF202019), Dubai, UAE, and a COVID-19 research grant (COV19-0307) from University of Sharjah, UAE. L. Imberti reported funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). L. Imberti and G.L. Marseglia reported funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). This research was partially supported by the Instituto de Salud Carlos III (COV20/0968). J. R. Heath reported funding from Biomedical Advanced Research and Development Authority HHSO10201600031C. S. Okada reports funding Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and development, AMED (Grant Number: JP20fk0108531). G. Gorochov was supported by ANR Flash COVID-19 program and SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs. The Three-City (3C) Study was conducted under a partnership agreement among the INSERM, the Victor Segalen–Bordeaux II University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme “Cohortes et collections de données biologiques”. S. Debette was supported by the University of Bordeaux Initiative of Excellence. P. K. Gregersen reports funding from the National Cancer Institute, NIH, under Contract No. 75N91019D00024, Task Order No. 75N91021F00001. J.W. is supported by an FWO Fundamental Clinical Mandate (1833317N). Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. Work at Vall d’Hebron was also partly supported by research funding from Instituto de Salud Carlos III grant PI17/00660 cofinanced by the European Regional Development Fund (ERDF). C.R.G. and colleagues of the Canarian Health System Sequencing Hub were supported by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334, Spanish Ministry of Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE); from Grupo DISA (OA18/017 and OA20/024); and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). CMB is supported by a MSFHR Health Professional-Investigator Award. PQH and LH were funded by the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650). Work at Y.-L. Lau’s laboratory in the University of Hong Kong (HKU) was supported by the Society for the Relief of Disabled Children. MBBS/PhD study of D.L. Leung in HKU was supported by the Croucher Foundation. J.L.F. was supported in part by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX (806-2018) and Colciencias contract 713-2016 (code 111574455633). A.K. was in part supported by grants NU20-05-00282 and NV18-05-00162 issued by the Czech Health Research Council and Ministry of Health, Czech Republic. L.P. was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617). I.M. is a Senior Clinical Investigator at the Research Foundation – Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. IM has received funding under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 948959)”. E.A. received funding from the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). M.V. received funding from the Sao Paulo Research Foundation (FAPESP) [grant number: 2020/09702-1] and JBS S.A [grant number 69004]. The NH-COVAIR was supported by a grant from the Meath Foundation.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

  • Marchal, Astrid
  • COVID Clinicians
  • Bolze, Alexandre
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer's Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (Equation 201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of business in EMEA, and the General Atlantic Foundation, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. A.N.S. is supported by European Union’s Horizon Health research and innovation program under grant agreement No. 101057100, project UNDINE. S.G.T. is supported by an Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a University of New South Wales Sydney COVID Rapid Response Initiative grant. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 10101616. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health and Fondation AP-HP Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0048). Y.Z. is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. This project has received funding from the Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959), the Swiss National Science Foundation (grant # 310030L_197721 to J.F.), and ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grants AJF202019 and AJF20259 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I. Erkizia, E. Grau, M. Massanella, and J. Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling, and processing.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Framework for quality assessment of whole genome cancer sequences

  • Whalley, Justin P.
  • Stobbe, Miranda D.
  • Beltran, Sergi
  • Gut, Marta
  • Trotta, Jean-Remi
  • Gut, Ivo Glynne
Bringing together cancer genomes from different projects increases power and allows the investigation of pan-cancer, molecular mechanisms. However, working with whole genomes sequenced over several years in different sequencing centres requires a framework to compare the quality of these sequences. We used the Pan-Cancer Analysis of Whole Genomes cohort as a test case to construct such a framework. This cohort contains whole cancer genomes of 2832 donors from 18 sequencing centres. We developed a non-redundant set of five quality control (QC) measurements to establish a star rating system. These QC measures reflect known differences in sequencing protocol and provide a guide to downstream analyses and allow for exclusion of samples of poor quality. We have found that this is an effective framework of quality measures. The implementation of the framework is available at: https://dockstore.org/containers/quay.io/jwerner_dkfz/pancanqc:1.2.2., J.P.W., M.D.S., S.B., M.G., J.T. and I.G.G. acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme. We also acknowledge the support through the European Union’s Horizon 2020-funded project EASI-Genomics under grant agreement no 824110. The funding bodies did not have any influence on the design of the study and collection, analysis, and interpretation of data and in writing the paper.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

  • Matuozzo, Daniela
  • Gut, Marta
  • Cobat, Aurélie
Background: We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15-20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases. Methods: We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded. Results: No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5-528.7, P = 1.1 × 10-4) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3-8.2], P = 2.1 × 10-4). This enrichment was further strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model (OR = 19.65[95%CI 2.1-2635.4], P = 3.4 × 10-3), and (2) considering as pLOF branchpoint variants with potentially strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3-8.4], P = 7.7 × 10-8). Finally, the patients with pLOF/bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients (56.0 [17.3] years; P = 1.68 × 10-5). Conclusions: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old. Trial registration: ClinicalTrials.gov NCT04262921 NCT04259892 NCT04352348., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program COVIFERON (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir—Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 10101616. P Bastard was supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20–0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). The COVIDeF study was supported by the French Ministry of Health, Fondation AP-HP et Programme Hospitalier de Recherche Clinique (PHRC COVID-19–20-0048) and was sponsored by APHP. Y.Z., O.M.D., L.D.N., H.C.S. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. G.N. and A.N. are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020–36663, GecoBiomark. I Meyts is a Senior Clinical Investigator at the Research Foundation – Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959). This work is supported by the Swiss National Science Foundation (grant # 310030L_197721 to JF). This work is supported by ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, and COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017–6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grant AJF202059 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I Erkizia, E Grau, M Massanella, and J Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling and processing.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

A method for multiplexed full-length single-molecule sequencing of the human mitochondrial genome

  • Keraite, Ieva
  • Becker, Philipp
  • Canevazzi, Davide
  • Frias-López, Cristina
  • Dabad, Marc
  • Tonda, Raúl
  • Paramonov, Ida
  • Ingham, Matthew
  • Brun-Heath, Isabelle
  • Leno, Jordi
  • Abulí, Anna
  • García-Arumí, Elena
  • Heath, Simon
  • Gut, Marta
  • Gut, Ivo Glynne
Methods to reconstruct the mitochondrial DNA (mtDNA) sequence using short-read sequencing come with an inherent bias due to amplification and mapping. They can fail to determine the phase of variants, to capture multiple deletions and to cover the mitochondrial genome evenly. Here we describe a method to target, multiplex and sequence at high coverage full-length human mitochondrial genomes as native single-molecules, utilizing the RNA-guided DNA endonuclease Cas9. Combining Cas9 induced breaks, that define the mtDNA beginning and end of the sequencing reads, as barcodes, we achieve high demultiplexing specificity and delineation of the full-length of the mtDNA, regardless of the structural variant pattern. The long-read sequencing data is analysed with a pipeline where our custom-developed software, baldur, efficiently detects single nucleotide heteroplasmy to below 1%, physically determines phase and can accurately disentangle complex deletions. Our workflow is a tool for studying mtDNA variation and will accelerate mitochondrial research., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 – EASI-Genomics (I.G.G.) and the ERC Synergy project BCLL@las under grant agreement No 810287 (I.G.G.). Institutional support was from the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias and cofunded with ERDF funds (PI19/01772). We acknowledge the institutional support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and institutional co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme to the institute.
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Evaluating the Impact of Sex-Biased Genetic Admixture in the Americas through the Analysis of Haplotype Data

  • Ongaro, Linda
  • Alarcón Riquelme, Marta Eugenia
This work was supported by the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.16-0030 to LO, LM, MM, FM; Project No. 2014-2020.4.01.16-0271 to RF; Project No. 2014-2020.4.01.16-0125 to RF; Project No. 2014-2020.4.01.16-0024 to LM, DM, LP; Project No. 2014-2020.4.01.15-0012 to MM; Project no. MOBEC008 to MM). This work was supported by the Estonian Research Council grant PUT (PRG243) to RF and MM and PUT (PRG1027) to KT. This research was supported by the European Union through Horizon 2020 research and innovation programme under grant no 810645 to MM and no 824110 to KT. AA and MRC received support from the Italian Ministry of Education, University and Research (MIUR) for Progetti PRIN2017 20174BTC4R and the Dipartimenti di Eccellenza Program (2018-2022)., A general imbalance in the proportion of disembarked males and females in the Americas has been documented during the Trans-Atlantic Slave Trade and the Colonial Era and, although less prominent, more recently. This imbalance may have left a signature on the genomes of modern-day populations characterised by high levels of admixture. The analysis of the uniparental systems and the evaluation of continental proportion ratio of autosomal and X chromosomes revealed a general sex imbalance towards males for European and females for African and Indigenous American ancestries. However, the consistency and degree of this imbalance are variable, suggesting that other factors, such as cultural and social practices, may have played a role in shaping it. Moreover, very few investigations have evaluated the sex imbalance using haplotype data, containing more critical information than genotypes. Here, we analysed genome-wide data for more than 5000 admixed American individuals to assess the presence, direction and magnitude of sex-biased admixture in the Americas. For this purpose, we applied two haplotype-based approaches, ELAI and NNLS, and we compared them with a genotype-based method, ADMIXTURE. In doing so, besides a general agreement between methods, we unravelled that the post-colonial admixture dynamics show higher complexity than previously described., European Commission 2014-2020.4.01.16-0030 2014-2020.4.01.16-0271 2014-2020.4.01.16-0125 2014-2020.4.01.16-0024 2014-2020.4.01.15-0012, MOBEC008, Estonian Research Council grant PUT PRG243 PRG1027, European Commission 810645 824110, Ministry of Education, Universities and Research (MIUR) PRIN2017 20174BTC4R
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

  • Zhang, Qian
  • Dorgham, Karim
  • Schlüter, Agatha
  • Quiros Roldan, Eugenia
  • Novelli, Giuseppe
  • Planas Serra, Laura
  • Rodríguez Palmero, Agustí
  • COVID-STORM Clinicians
  • COVID Clinicians
  • Imagine COVID Group
  • French COVID Cohort Study Group
  • CoV-Contact Cohort
  • Amsterdam UMC Covid-19 Biobank
  • COVID Human Genetic Effort
  • NIAID-USUHS/TAGC COVID Immunity Group
Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3-and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

  • Asano, Takaki
  • Boisson, Bertrand
  • Onodi, Fanny
  • Matuozzo, Daniela
  • Moncada Velez, Marcela
  • Maglorius Renkilaraj, Majistor Raj Luxman
  • Zhang, Peng
  • Meertens, Laurent
  • Bolze, Alexandre
  • Materna, Marie
  • Korniotis, Sarantis
  • Khan, Taushif
  • Spaan, András N.
  • Bonfanti, Paolo
  • Tubiana, Sarah
  • Burdet, Charles
  • Nussbaum, Robert L.
  • Kahn-Kirby, Amanda
  • Snow, Andrew L.
  • Bustamante, Jacinta
  • Puel, Anne
  • Lifton, Richard P.
  • Boisson-Dupuis, Stéphanie
  • Notarangelo, Luigi D.
  • Zhang, Shen-Ying
  • Su, Helen C.
  • Béziat, Vivien
  • Bastard, Paul
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Amara, Ali
  • Soumelis, Vassili
  • Cobat, Aurélie
  • Zhang, Qian
  • Casanova, Jean-Laurent
  • COVID Human Genetic Effort
  • French COVID Cohort Study Group
  • COVID-STORM Clinicians
  • Amsterdam UMC Covid-19 Biobank
  • COVID Clinicians
  • Gervais, Adrian
  • Imagine COVID Group
  • CoV-Contact Cohort
  • NIAID-USUHS COVID Study Group
  • Talouarn, Estelle
  • Bigio, Benedetta
  • Seeleuthner, Yoann
  • Bilguvar, Kaya
  • Zhang, Yu
  • Neehus, Anna-Lena
  • Ogishi, Masato
  • Soler Palacín, Pere
  • Pelham, Simon J.
  • Martin Nalda, Andrea
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Colobran, Roger
  • Rivière, Jacques G.
  • Tandjaoui-Lambiotte, Yacine
  • Chaïbi, Khalil
  • Shahrooei, Mohammad
  • Darazam, Ilad Alavi
  • Olyaei, Nasrin Alipour
  • Mansouri, Davood
  • Hatipoğlu, Nevin
  • Casari, Giorgio
  • Palabiyik, Figen
  • Carrera, Paola
  • Ozcelik, Tayfun
  • Novelli, Giuseppe
  • Novelli, Antonio
  • Aiuti, Alessandro
  • Bondesan, Simone
  • Barzaghi, Federica
  • Rovere-Querini, Patrizia
  • Tresoldi, Cristina
  • Franco, Jose Luis
  • Rojas, Julian
  • Reyes, Luis Felipe
  • Bustos, Ingrid G.
  • Planas Serra, Laura
  • Arias, Andres Augusto
  • Gut, Marta
  • Morelle, Guillaume
  • Christèle, Kyheng
  • Troya, Jesús
  • Schlüter, Agatha
  • Pujol, Aurora, 1968-
  • Allende, Luis M.
  • Rodriguez Gallego, Carlos
  • Flores, Carlos
  • Cabrera Marante, Oscar
  • Pleguezuelo, Daniel E.
  • Pérez de Diego, Rebeca
  • Keles, Sevgi
  • Brodin, Petter
  • Aytekin, Gokhan
  • Smith, C.I. Edvard
  • Akcan, Ozge Metin
  • Bryceson, Yenan T.
  • Bergman, Peter
  • Smole, Daniel
  • Norlin, Anna-Carin
  • Campbell, Tessa M.
  • Covill, Laura E.
  • Hammarström, Lennart
  • Pan-Hammarström, Qiang
  • Abolhassani, Hassan
  • Mane, Shrikant
  • Marr, Nico
  • Dalgard, Clifton L.
  • Ata, Manar
  • Biondi, Andrea
  • Al Ali, Fatima
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10-5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4 We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7 The patients' blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

  • Manry, Jérémy
  • Bastard, Paul
  • Gervais, Adrian
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Michailidis, Eleftherios
  • Hoffmann, Hans-Heinrich
  • Eto, Shohei
  • García-Prat, Marina
  • Bizien, Lucy
  • Raoult, Didier
  • Vasse, Marc
  • Gregersen, Peter K.
  • Piemonti, Lorenzo
  • Rodríguez-Gallego, Carlos
  • Notarangelo, Luigi D.
  • Su, Helen C.
  • Kisand, Kai
  • Okada, Satoshi
  • Luyt, Charles-Edouard
  • Lau, Yu-Lung
  • Puel, Anne
  • Jouanguy, Emmanuelle
  • Rice, Charles M.
  • Tiberghien, Pierre
  • Zhang, Qian
  • Casanova, Jean-Laurent
  • Abel, Laurent
  • Cobat, Aurélie
  • Amador-Borrero, Blanca
  • Gaudet, Alexandre
  • Leung, Daniel
  • Poissy, Julien
  • Morel, Pascal
  • Richard, Pascale
  • Cognasse, Fabrice
  • Troya, Jesús
  • Trouillet-Assant, Sophie
  • Belot, Alexandre
  • Saker, Kahina
  • Garçon, Pierre
  • Rivière, Jacques G.
  • Coulongeat, Matthieu
  • Lagier, Jean-Christophe
  • Gentile, Stephanie
  • Rosen, Lindsey B.
  • Shaw, Elana
  • Morio, Tomohiro
  • Tanaka, Junko
  • Dalmau, David
  • Tharaux, Pierre-Louis
  • Sene, Damien
  • Stépanian, Alain
  • Marlet, Julien
  • Mégarbane, Bruno
  • Triantafyllia, Vasiliki
  • Fekkar, Arnaud
  • Heath, James R.
  • Franco, José Luis
  • Anaya, Juan Manuel
  • Solé-Violán, Jordi
  • Imberti, Luisa
  • Biondi, Andrea
  • Bonfanti, Paolo
  • Koning, Rutger
  • Castagnoli, Riccardo
  • Delmonte, Ottavia M.
  • Zhang, Yu
  • Snow, Andrew L.
  • Holland, Steven M.
  • Biggs, Catherine M.
  • Moncada-Velez, Marcela
  • Arias, Andrés Augusto
  • Lorenzo, Lazaro
  • Boucherit, Soraya
  • Reyes, Luis Felipe
  • Anglicheau, Dany
  • Planas, Anna M.
  • Haerynck, Filomeen
  • Duvlis, Sotirija
  • Ozcelik, Tayfun
  • Keles, Sevgi
  • Bousfiha, Ahmed Aziz
  • El Bakkouri, Jalila
  • Ramírez-Santana, Carolina
  • Paul, Stephanie
  • Chauvineau-Grenier, Angélique
  • Pan-Hammarström, Qiang
  • Hammarström, Lennart
  • Dupont, Annabelle
  • Kurolap, Alina
  • Metz, Christine N.
  • Aiuti, Alessandro
  • Casari, Giorgio
  • Lampasona, Vito
  • Ciceri, Fabio
  • Barreiros, Lucila
  • Venet, Fabienne
  • Domínguez-Garrido, Elena
  • Vidigal, Mateus
  • Zatz, Mayana
  • Beek, Diederik van der
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Stepanovskyy, Yurii
  • Boyarchuk, Oksana
  • Nukui, Yoko
  • Tsumura, Miyuki
  • Monneret, Guillaume
  • Vidaur, Loreto
  • Tangye, Stuart G.
  • Burrel, Sonia
  • Duffy, Darragh
  • Quintana-Murci, Lluis
  • Klocperk, Adam
  • Kann, Nelli Y.
  • Shcherbina, Anna
  • Nussenzweig, Michel C.
  • Parra-Martínez, Alba
  • Arrestier, Romain
  • Boudhabhay, Idris
  • Baris-Feldman, Hagit
  • Hagin, David
  • Wauters, Joost
  • Meyts, Isabelle
  • Dyer, Adam H.
  • Kennelly, Sean P.
  • Bourke, Nollaig M.
  • Halwani, Rabih
  • Yang, Rui
  • Sharif-Askari, Fatemeh Saheb
  • Dorgham, Karim
  • Sallette, Jérôme
  • Mehlal-Sedkaoui, Souad
  • Alkhater, Suzan
  • Rigo-Bonnin, Raúl
  • Morandeira, Francisco
  • Roussel, Lucie
  • Vinh, Donald C.
  • Erikstrup, Christian
  • Haljasmägi, Liis
  • Condino-Neto, Antonio
  • Prando, Carolina
  • Bondarenko, Anastasiia
  • Spaan, András N.
  • Gilardin, Laurent
  • Fellay, Jacques
  • Lyonnet, Stanislas
  • Bilguvar, Kaya
  • Lifton, Richard P.
  • Mane, Shrikant M.
  • Migaud, Mélanie
  • HGID Lab
  • COVID Clinicians
  • COVID-STORM Clinicians
  • NIAID Immune Response to COVID Group
  • NH-COVAIR Study Group
  • Danish CHGE
  • Danish Blood Donor Study
  • St. James's Hospital SARS CoV2 Interest Group
  • French COVID Cohort Study Group
  • Imagine COVID Group
  • Särekannu, Karita
  • The Milieu Intérieur Consortium
  • CoV-Contact Cohort
  • Amsterdam UMC Covid-19 Biobank Investigators
  • COVID Human Genetic Effort
  • CP-COVID-19 Group
  • Constances Cohort
  • 3C-Dijon Study
  • Cerba Health-Care
  • Etablissement Français du Sang Study group
  • Anderson, MarK S.
  • Maslovskaja, Julia
  • Boisson, Bertrand
  • Béziat, Vivien
  • Zhang, Shen-Ying
  • Andreakos, Evangelos
  • Hermine, Olivier
  • Pujol, Aurora
  • Peterson, Pärt
  • Mogensen, Trine
  • Rowen, Lee
  • Mond, James
  • Prost, Nicolas de
  • Debette, Stephanie
  • Lamballerie, Xavier de
  • Burdet, Charles
  • Bouadma, Lila
  • Zins, Marie
  • Soler-Palacín, Pere
  • Colobran, Roger
  • Gorochov, Guy
  • Solanich, Xavier
  • Susen, Sophie
  • Tandjaoui-Lambiotte, Yacine
  • Martínez-Picado, Javier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and ≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; The Rockefeller University; the St. Giles Foundation; the NIH (Grants R01AI088364 and R01AI163029); the National Center for Advancing Translational Sciences; NIH Clinical and Translational Science Awards program (Grant UL1 TR001866); a Fast Grant from Emergent Ventures; Mercatus Center at George Mason University; the Yale Center for Mendelian Genomics and the Genome Sequencing Program Coordinating Center funded by the National Human Genome Research Institute (Grants UM1HG006504 and U24HG008956); the Yale High Performance Computing Center (Grant S10OD018521); the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (Grant ANR-10-IAHU-01); the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (Grant ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (Grant EQU201903007798); the French Agency for Research on AIDS and Viral hepatitis (ANRS) Nord-Sud (Grant ANRS-COV05); the ANR GENVIR (Grant ANR-20-CE93-003), AABIFNCOV (Grant ANR-20-CO11-0001), CNSVIRGEN (Grant ANR-19-CE15-0009-01), and GenMIS-C (Grant ANR-21-COVR-0039) projects; the Square Foundation; Grandir–Fonds de solidarité pour l’Enfance; the Fondation du Souffle; the SCOR Corporate Foundation for Science; The French Ministry of Higher Education, Research, and Innovation (Grant MESRI-COVID-19); Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM; and the University Paris Cité. P. Bastard was supported by the FRM (Award EA20170638020). P. Bastard., J.R., and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of Fondation Bettencourt Schueller). Work at the Neurometabolic Disease lab received funding from Centre for Biomedical Research on Rare Diseases (CIBERER) (Grant ACCI20-767) and the European Union's Horizon 2020 research and innovation program under grant agreement 824110 (EASI Genomics). Work in the Laboratory of Virology and Infectious Disease was supported by the NIH (Grants P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1), a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The Infanta Leonor University Hospital supported the research of the Department of Internal Medicine and Allergology. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). This work was also partly supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research, NIH (Grants ZIA AI001270 to L.D.N. and 1ZIAAI001265 to H.C.S.). This program is supported by the Agence Nationale de la Recherche (Grant ANR-10-LABX-69-01). K.K.’s group was supported by the Estonian Research Council, through Grants PRG117 and PRG377. R.H. was supported by an Al Jalila Foundation Seed Grant (Grant AJF202019), Dubai, United Arab Emirates, and a COVID-19 research grant (Grant CoV19-0307) from the University of Sharjah, United Arab Emirates. S.G.T. is supported by Investigator and Program Grants awarded by the National Health and Medical Research Council of Australia and a University of New South Wales COVID Rapid Response Initiative Grant. L.I. reports funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). This research was partially supported by the Instituto de Salud Carlos III (Grant COV20/0968). J.R.H. reports funding from Biomedical Advanced Research and Development Authority (Grant HHSO10201600031C). S.O. reports funding from Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and Development (Grant JP20fk0108531). G.G. was supported by the ANR Flash COVID-19 program and SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University iCOVID programs. The 3C Study was conducted under a partnership agreement between INSERM, Victor Segalen Bordeaux 2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also supported by the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Direction générale de la Santé, Mutuelle Générale de l’Education Nationale, Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Program “Cohortes et collections de données biologiques.” S. Debette was supported by the University of Bordeaux Initiative of Excellence. P.K.G. reports funding from the National Cancer Institute, NIH, under Contract 75N91019D00024, Task Order 75N91021F00001. J.W. is supported by a Research Foundation - Flanders (FWO) Fundamental Clinical Mandate (Grant 1833317N). Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. Work at Vall d’Hebron was also partly supported by research funding from Instituto de Salud Carlos III Grant PI17/00660 cofinanced by the European Regional Development Fund (ERDF/FEDER). C.R.-G. and colleagues from the Canarian Health System Sequencing Hub were supported by the Instituto de Salud Carlos III (Grants COV20_01333 and COV20_01334), the Spanish Ministry for Science and Innovation (RTC-2017-6471-1; AEI/FEDER, European Union), Fundación DISA (Grants OA18/017 and OA20/024), and Cabildo Insular de Tenerife (Grants CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). T.H.M. was supported by grants from the Novo Nordisk Foundation (Grants NNF20OC0064890 and NNF21OC0067157). C.M.B. is supported by a Michael Smith Foundation for Health Research Health Professional-Investigator Award. P.Q.H. and L. Hammarström were funded by the European Union’s Horizon 2020 research and innovation program (Antibody Therapy Against Coronavirus consortium, Grant 101003650). Work at Y.-L.L.’s laboratory in the University of Hong Kong (HKU) was supported by the Society for the Relief of Disabled Children. MBBS/PhD study of D.L. in HKU was supported by the Croucher Foundation. J.L.F. was supported in part by the Evaluation-Orientation de la Coopération Scientifique (ECOS) Nord - Coopération Scientifique France-Colombie (ECOS-Nord/Columbian Administrative department of Science, Technology and Innovation [COLCIENCIAS]/Colombian Ministry of National Education [MEN]/Colombian Institute of Educational Credit and Technical Studies Abroad [ICETEX, Grant 806-2018] and Colciencias Contract 713-2016 [Code 111574455633]). A. Klocperk was, in part, supported by Grants NU20-05-00282 and NV18-05-00162 issued by the Czech Health Research Council and Ministry of Health, Czech Republic. L.P. was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (Grant COVID-2020-12371617). I.M. is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies (PID); by the Katholieke Universiteit Leuven C1 Grant C16/18/007; by a Flanders Institute for Biotechnology-Grand Challenges - PID grant; by the FWO Grants G0C8517N, G0B5120N, and G0E8420N; and by the Jeffrey Modell Foundation. I.M. has received funding under the European Union’s Horizon 2020 research and innovation program (Grant Agreement 948959). E.A. received funding from the Hellenic Foundation for Research and Innovation (Grant INTERFLU 1574). M. Vidigal received funding from the São Paulo Research Foundation (Grant 2020/09702-1) and JBS SA (Grant 69004). The NH-COVAIR study group consortium was supported by a grant from the Meath Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection

  • Andreakos, Evangelos
  • Abel, Laurent
  • Vinh, Donald C.
  • Kaja, Elżbieta
  • Drolet, Beth A.
  • Zhang, Qian
  • O’Farrelly, Cliona
  • Novelli, Giuseppe
  • Rodríguez-Gallego, Carlos
  • Haerynck, Filomeen
  • Prando, Carolina
  • Pujol, Aurora
  • COVID Human Genetic Effort
  • Su, Helen C.
  • Casanova, Jean-Laurent
  • Spaan, András N.
SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COVID-19 cases among SARS-CoV-2-infected individuals. By contrast, the genetic and immunological determinants of resistance to infection per se remain unknown. Following the discovery that autosomal recessive deficiency in the DARC chemokine receptor confers resistance to Plasmodium vivax, autosomal recessive deficiencies of chemokine receptor 5 (CCR5) and the enzyme FUT2 were shown to underlie resistance to HIV-1 and noroviruses, respectively. Along the same lines, we propose a strategy for identifying, recruiting, and genetically analyzing individuals who are naturally resistant to SARS-CoV-2 infection., The Laboratory of Human Genetics of Infectious Diseases is supported by the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the Investments for the Future program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS-COV05, the Fondation du Souffle, the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM), and the University of Paris. E.A. is supported by research grants from the European Commission’s Horizon 2020 research and innovation program (IMMUNAID, grant no. 779295, CURE, grant no. 767015 and TO_AITION grant no. 848146) and the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). C.O.F. is supported in part by the Science Foundation Ireland COVID-19 Program. G.N. is supported by a grant awarded to Regione Lazio (Research Group Projects 2020) no. A0375-2020-36663, GecoBiomark. A.P. is supported in part by the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342) and the CERCA Program/Generalitat de Catalunya. H.S. is supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. A.S. is supported in part by the European Union’s Horizon 2020 research and innovation program (Marie Sklodowska-Curie grant no. 789645).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

  • Zhang, Qian
  • Pizzorno, Andrés
  • Miorin, Lisa
  • Bastard, Paul
  • Gervais, Adrian
  • Le Voyer, Tom
  • Bizien, Lucy
  • Manry, Jeremy
  • Rosain, Jérémie
  • Philippot, Quentin
  • Goavec, Kelian
  • Padey, Blandine
  • Cupic, Anastasija
  • Laurent, Emilie
  • Saker, Kahina
  • Vanker, Martti
  • Särekannu, Karita
  • García-Salum, Tamara
  • Ferres, Marcela
  • Le Corre, Nicole
  • Sánchez-Céspedes, Javier
  • Balsera-Manzanero, María
  • Carratalà, Jordi
  • Retamar Gentil, Pilar
  • Abelenda, Gabriela
  • Valiente-Méndez, Adoración
  • Tiberghien, Pierre
  • Zins, Marie
  • Debette, Stéphanie
  • Meyts, Isabelle
  • Haerynck, Filomeen
  • Castagnoli, Riccardo
  • Notarangelo, Luigi D.
  • González-Granado, Luis
  • Domínguez-Pinilla, Nerea
  • Andreakos, Evangelos
  • Triantafyllia, Vasiliki
  • Rodríguez-Gallego, Carlos
  • Solé-Violán, Jordi
  • Ruiz-Hernández, José Juan
  • Rodríguez de Castro, Felipe
  • Ferreres-Franco, José
  • Briones, Marisa
  • Wauters, Joost
  • Vanderbeke, Lore
  • Feys, Simon
  • Kuo, Chen-Yen
  • Lei, Wei-Te
  • Ku, Cheng-Lung
  • Tal, Galit
  • Etzioni, Amos
  • Hanna, Suhair
  • Fournet, Thomas
  • Casalegno, Jean-Sebastien
  • Queromes, Gregory
  • Argaud, Laurent
  • Javouhey, Etienne
  • Rosa-Calatrava, Manuel
  • Cordero, Elisa
  • Aydillo, T. A.
  • Medina López, Rafael Antonio
  • Kisand, Kai
  • Puel, Anne
  • Jouanguy, Emmanuelle
  • Abel, Laurent
  • Cobat, Aurélie
  • Trouillet-Assant, Sophie
  • García-Sastre, Adolfo
  • Casanova, Jean-Laurent
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10-5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10-10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH; R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences, NIH Clinical and Translational Science Award program (UL1 TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (EQU201903007798), the ANRS-COV05, ANR-RHU program ANR-21-RHUS-08, ANR GENVIR (ANR-20-CE93-003), ANR GenMISC (ANR-21-COVR-0039), and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir–Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, and the Université Paris Cité. This work was partly supported by the Center for Research on Influenza Pathogenesis and Transmission, a National Institute of Allergy and Infectious Diseases (NIAID)–funded Center of Excellence for Influenza Research and Response (contract no. 75N93021C00014), and the FLUOMICS Consortium (NIH-NIAID grant U19AI135972) to both A. García-Sastre and R.A. Medina, and by NIAID grant U19AI142733 and U19AI168631 to A. García-Sastre. Work in the Medina laboratory was also supported by the PIA ACT 1408, FONDECYT 1161971 and 1212023 grants from Agencia Nacional de Investigación y Desarrollo of Chile. The VirPath team is supported by INSERM REACTing (Research & Action Emerging Infectious Diseases), CNRS, and Mérieux Research grants. B. Padey is supported by an ANRT CIFRE PhD scholarship. For the Lyon cohort, specimen collection and study was supported by a grant from the French Ministry of Health PHRC-I 2013 ANTIGRIPPE. C. Rodríguez-Gallego and colleagues were supported by the Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI12/01565, Spanish Ministry for Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE), Grupo DISA, Fundación MAPFRE Guanarteme, Sociedad Española de Neumología y Cirugía Torácica and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas, científicas del Instituto Tecnológico y de Energías Renovables para colaborar en la lucha contra la COVID-19”). E. Andreakos is supported by the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). P. Bastard was supported by the French Foundation for Medical Research (EA20170638020) and by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). This study was supported by Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0009); cofinanced by European Regional Development Fund “A way to achieve Europe”; Operative Program Intelligence Growth 2014-2020 (CB21/13/00006) also was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea–Next Generation EU and Consejería de Economía, Conocimiento, Empresas y Universidad, Secretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía, Spain (P18-RT-3320). I. Meyts is a Senior Clinical Investigator at the Research Foundation–Flanders and is supported by the CSL Behring Chair of Primary Immunodeficiencies, a CSL-Behring Research Grant, KU Leuven C1 grant C16/18/007, a VIB GC PID Grant, Fonds Wetenschappelijk Onderzoek grants G0C8517N, G0B5120N, and G0E8420N, and the Jeffrey Modell Foundation. Open Access funding provided by Rockefeller University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Human genetic and immunological determinants of critical COVID-19 pneumonia

  • Zhang, Qian
  • Bastard, Paul
  • COVID Human Genetic Effort
  • Cobat, Aurelie
  • Casanova, Jean-Laurent
  • Planas, Anna M.
COVID Human Genetic Effort: Adem Karbuz, Adrian Gervais, Ahmad Abou Tayoun, Alessandro Aiuti, Alexandre Belot, Alexandre Bolze, Alexandre Gaudet, Anastasiia Bondarenko, Zhiyong Liu, András N. Spaan, Andrea Guennoun, Andres Augusto Arias, Anna M. Planas, Anna Sediva, Anna Shcherbina, Anna-Lena Neehus, Anne Puel, Antoine Froidure, Antonio Novelli, Aslınur Özkaya Parlakay, Aurora Pujol, Aysun Yahşi, Belgin Gülhan, Benedetta Bigio, Bertrand Boisson, Beth A. Drolet, Carlos Andres Arango Franco, Carlos Flores, Carlos Rodríguez-Gallego, Carolina Prando, Catherine M. Biggs, Charles-Edouard Luyt, Clifton L. Dalgard, Cliona O’Farrelly, Daniela Matuozzo, David Dalmau, David S. Perlin, Davood Mansouri, Diederik van de Beek, Donald C. Vinh, Elena Dominguez-Garrido, Elena W. Y. Hsieh, Emine Hafize Erdeniz, Emmanuelle Jouanguy, Esra Şevketoglu, Estelle Talouarn, Eugenia Quiros-Roldan, Evangelos Andreakos, Eystein Husebye, Fahad Alsohime, Filomeen Haerynck, Giorgio Casari, Giuseppe Novelli, Gökhan Aytekin, Guillaume Morelle, Gulsum Alkan, Gulsum Iclal Bayhan, Hagit Baris Feldman, Helen C. Su, Horst von Bernuth, Igor Resnick, Ingrid Bustos, Isabelle Meyts, Isabelle Migeotte, Ivan Tancevski, Jacinta Bustamante, Jacques Fellay, Jamila El Baghdadi, Javier Martinez-Picado, Jean-Laurent Casanova, Jeremie Rosain, Jeremy Manry, Jie Chen, John Christodoulou, Jonathan Bohlen, José Luis Franco, Juan Li, Juan Manuel Anaya, Julian Rojas, Junqiang Ye, K. M. Furkan Uddin, Kadriye Kart Yasar, Kai Kisand, Keisuke Okamoto, Khalil Chaïbi, Kristina Mironska, László Maródi, Laurent Abel, Laurent Renia, Lazaro Lorenzo, Lennart Hammarström, Lisa F. P. Ng, Lluis Quintana-Murci, Lucia Victoria Erazo, Luigi D. Notarangelo, Luis Felipe Reyes, Luis M. Allende, Luisa Imberti, Majistor Raj Luxman Maglorius Renkilaraj, Marcela Moncada-Velez, Marie Materna, Mark S. Anderson, Marta Gut, Marwa Chbihi, Masato Ogishi, Melike Emiroglu, Mikko R. J. Seppänen, Mohammed J. Uddin, Mohammed Shahrooei, Natalie Alexander, Nevin Hatipoglu, Nico Marr, Nihal Akçay, Oksana Boyarchuk, Ondrej Slaby, Ozge Metin Akcan, Peng Zhang, Pere Soler-Palacín, Peter K. Gregersen, Petter Brodin, Pierre Garçon, Pierre-Emmanuel Morange, Qiang Pan-Hammarström, Qinhua Zhou, Quentin Philippot, Rabih Halwani, Rebeca Perez de Diego, Romain Levy, Rui Yang, Şadiye Kübra Tüter Öz, Saleh Al Muhsen, Saliha Kanık-Yüksek, Sara Espinosa-Padilla, Sathishkumar Ramaswamy, Satoshi Okada, Sefika Elmas Bozdemir, Selma Erol Aytekin, Şemsi Nur Karabela, Sevgi Keles, Sevtap Senoglu, Shen-Ying Zhang, Sotirija Duvlis, Stefan N. Constantinescu, Stephanie Boisson-Dupuis, Stuart E. Turvey, Stuart G. Tangye, Takaki Asano, Tayfun Ozcelik, Tom Le Voyer, Tom Maniatis, Tomohiro Morio, Trine H. Mogensen, Vanessa Sancho-Shimizu, Vivien Beziat, Xavier Solanich, Yenan Bryceson, Yu-Lung Lau & Yuval Itan, SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases. The ensuing risk of death (approximately 1% across age and gender) doubles every five years from childhood onwards and is around 1.5 times greater in men than in women. Here we review the molecular and cellular determinants of critical COVID-19 pneumonia. Inborn errors of type I interferons (IFNs), including autosomal TLR3 and X-chromosome-linked TLR7 deficiencies, are found in around 1–5% of patients with critical pneumonia under 60 years old, and a lower proportion in older patients. Pre-existing auto-antibodies neutralizing IFNα, IFNβ and/or IFNω, which are more common in men than in women, are found in approximately 15–20% of patients with critical pneumonia over 70 years old, and a lower proportion in younger patients. Thus, at least 15% of cases of critical COVID-19 pneumonia can be explained. The TLR3- and TLR7-dependent production of type I IFNs by respiratory epithelial cells and plasmacytoid dendritic cells, respectively, is essential for host defence against SARS-CoV-2. In ways that can depend on age and sex, insufficient type I IFN immunity in the respiratory tract during the first few days of infection may account for the spread of the virus, leading to pulmonary and systemic inflammation., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI163029), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, the Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the ‘Investments for the Future’ program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS Nord-Sud (ANRS-COV05), ANR grant GENVIR (ANR-20-CE93-003), ANR AABIFNCOV (ANR-20-CO11-0001) and ANR MIS-C (ANR 21-COVR-0039, GenMIS-C) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-Genomics), the Square Foundation, Grandir—Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, Fondation du Souffle, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM, and the University of Paris. P.B. was supported by the FRM (EA20170638020) and the MD-PhD programme of the Imagine Institute (with the support of the Fondation Bettencourt Schueller). G.N. is supported by Regione Lazio (Research Group Projects 2020) no. A0375-2020-36663, GecoBiomark. H.C.S. and L.D.N. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

  • Bastard, Paul
  • Vazquez, Sara E.
  • Liu, Jamin
  • Laurie, Matthew T.
  • Wang, Chung Yu
  • Gervais, Adrian
  • Le Voyer, Tom
  • Bizien, Lucy
  • Zamecnik, Colin
  • Philippot, Quentin
  • Rosain, Jérémie
  • Allende, Luis M.
  • Martinez-Picado, Javier
  • Ozcelik, Tayfun
  • Imberti, Luisa
  • Notarangelo, Luigi D.
  • Troya, Jesus
  • Solanich, Xavier
  • Zhang, Shen-Ying
  • Puel, Anne
  • Wilson, Michael R.
  • Trouillet-Assant, Sophie
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Ye, Chun Jimmie
  • Cobat, Aurélie
  • Thompson, Leslie M.
  • Andreakos, Evangelos
  • Zhang, Qian
  • Anderson, Mark S.
  • Casanova, Jean-Laurent
  • DeRisi, Joseph L.
  • Catherinot, Emilie
  • Willmore, Andrew
  • Mitchell, Anthea M.
  • Bair, Rebecca
  • Garçon, Pierre
  • Kenney, Heather
  • Fekkar, Arnaud
  • Salagianni, Maria
  • Poulakou, Garyphallia
  • Siouti, Eleni
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Weiss, Günter
  • Nagl, Laurenz
  • Manry, Jérémy
  • Duvlis, Sotirija
  • Arroyo-Sánchez, Daniel
  • Paz Artal, Estela
  • Rubio, Luis
  • Perani, Cristiano
  • Bezzi, Michela
  • Sottini, Alessandra
  • Quaresima, Virginia
  • Roussel, Lucie
  • Vinh, Donald C.
  • Reyes, Luis Felipe
  • Garzaro, Margaux
  • Hatipoglu, Nevin
  • Boutboul, David
  • Tandjaoui-Lambiotte, Yacine
  • Borghesi, Alessandro
  • Aliberti, Anna
  • Cassaniti, Irene
  • Venet, Fabienne
  • Monneret, Guillaume
  • Halwani, Rabih
  • Sharif-Askari, Narjes Saheb
  • Danielson, Jeffrey
  • Burrel, Sonia
  • Morbieu, Caroline
  • Stepanovskyy, Yurii
  • Bondarenko, Anastasia
  • Volokha, Alla
  • Boyarchuk, Oksana
  • Gagro, Alenka
  • Neuville, Mathilde
  • Neven, Bénédicte
  • Keles, Sevgi
  • Hernu, Romain
  • Bal, Antonin
  • Novelli, Antonio
  • Novelli, Giuseppe
  • Saker, Kahina
  • Ailioaie, Oana
  • Antolí, Arnau
  • Jeziorski, Eric
  • Rocamora-Blanch, Gemma
  • Teixeira, Carla
  • Delaunay, Clarisse
  • Lhuillier, Marine
  • Le Turnier, Paul
  • Zhang, Yu
  • Mahevas, Matthieu
  • Pan-Hammarström, Qiang
  • Abolhassani, Hassan
  • Bompoil, Thierry
  • Dorgham, Karim
  • Gorochov, Guy
  • Laouenan, Cédric
  • Rodríguez-Gallego, Carlos
  • Ng, Lisa F. P.
  • Renia, Laurent
  • Pujol, Aurora
  • Belot, Alexandre
  • Raffi, François
Life-threatening "breakthrough" cases of critical COVID-19 are attributed to poor or waning antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting auto-Abs neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; their contribution to hypoxemic breakthrough cases in vaccinated people is unknown. We studied a cohort of 48 individuals (aged 20 to 86 years) who received two doses of a messenger RNA (mRNA) vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Ab levels to the vaccine, neutralization of the virus, and auto-Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal Ab response to the vaccine. Among them, 10 (24%) had auto-Abs neutralizing type I IFNs (aged 43 to 86 years). Eight of these 10 patients had auto-Abs neutralizing both IFN-α2 and IFN-ω, whereas two neutralized IFN-ω only. No patient neutralized IFN-β. Seven neutralized type I IFNs at 10 ng/ml and three at 100 pg/ml only. Seven patients neutralized SARS-CoV-2 D614G and Delta efficiently, whereas one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only type I IFNs at 100 pg/ml neutralized both D614G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating Abs capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a notable proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute; The Rockefeller University; the St. Giles Foundation; the NIH (R01AI088364 and R01AI163029); the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866); a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University; the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the program “Investissement d’Avenir” launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) with references ANR-21-RHUS-08 and ANR-10-IAHU-01; the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM; EQU201903007798); the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), ANR AABIFNCOV (ANR-20-CO11-0001), and ANR GenMISC (ANR-21-COVR-0039) projects; the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 824110 (EASI-genomics); the Square Foundation; Grandir–Fonds de solidarité pour l’enfance; the Fondation du Souffle; the SCOR Corporate Foundation for Science; the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19); Institut National de la Santé et de la Recherche Médicale (INSERM); REACTing-INSERM; and the University of Paris. C.R.-G., R.P.D., and C.F. were funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43California grant no. 779295). L.R. and L.F.P.N. were supported by Singapore National Medical Research Council COVID-19 Research Fund (COVID19RF-001, COVID19RF-007, COVID19RF-0008, and COVID19RF-060) and A*STAR COVID-19 Research funding (H/20/04/g1/006). The UCSF COMET Consortium is supported by the Clinical and Translational Science Institute University of California, San Francisco and the NIH (U19AI077439). A.A., G.R.-B., and X.S. are funded by the 202115-31 project, funded by La Marató de TV3. L.D.N. was supported by the intramural Research Program of the NIAID, NIH. J.L.D. is supported by the Chan Zuckerberg Biohub. We acknowledge the support of the Chao Family Comprehensive Cancer Center Experimental Tissue Shared Resource, supported by the National Cancer Institute of the NIH under award number P30CA062203. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. P.B. was supported by the FRM (EA20170638020). P.B. and T.L.V. were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autoantibodies against type I IFNs in humans with alternative NF-¿B pathway deficiency

  • Le Voyer, Tom
  • Pérez-Tur, Jordi
  • NF-κB Consortium
  • COVID Human Genetic Effort
  • Puel, Anne
32 páginas, 5 figuras, 10 figuras en material suplementario. Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions (NF-κB Consortium & COVID Human Genetic Effort authors) and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-023-06717-x., Patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1) caused by autosomal recessive AIRE deficiency produce autoantibodies that neutralize type I interferons (IFNs)1,2, conferring a predisposition to life-threatening COVID-19 pneumonia3. Here we report that patients with autosomal recessive NIK or RELB deficiency, or a specific type of autosomal-dominant NF-κB2 deficiency, also have neutralizing autoantibodies against type I IFNs and are at higher risk of getting life-threatening COVID-19 pneumonia. In patients with autosomal-dominant NF-κB2 deficiency, these autoantibodies are found only in individuals who are heterozygous for variants associated with both transcription (p52 activity) loss of function (LOF) due to impaired p100 processing to generate p52, and regulatory (IκBδ activity) gain of function (GOF) due to the accumulation of unprocessed p100, therefore increasing the inhibitory activity of IκBδ (hereafter, p52LOF/IκBδGOF). By contrast, neutralizing autoantibodies against type I IFNs are not found in individuals who are heterozygous for NFKB2 variants causing haploinsufficiency of p100 and p52 (hereafter, p52LOF/IκBδLOF) or gain-of-function of p52 (hereafter, p52GOF/IκBδLOF). In contrast to patients with APS-1, patients with disorders of NIK, RELB or NF-κB2 have very few tissue-specific autoantibodies. However, their thymuses have an abnormal structure, with few AIRE-expressing medullary thymic epithelial cells. Human inborn errors of the alternative NF-κB pathway impair the development of AIRE-expressing medullary thymic epithelial cells, thereby underlying the production of autoantibodies against type I IFNs and predisposition to viral diseases., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St Giles Foundation, the National Institutes of Health (NIH) (R01AI088364, R01AI127564-06 and R01AI163029), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) programme (UL1 TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR) under the ‘Investments for the Future’ programme (ANR10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), ANR AABIFNCOV (ANR-20-CO11-0001), ANR AAILC (ANR-21-LIBA-0002) and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU programme (ANR-21-RHUS-08-COVIFERON), the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 824110 (EASI-genomics), the HORIZONHLTH-2021-DISEASE-04 programme under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir—Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM) and of Paris Cité University. J.R. was supported by the INSERM PhD programme (poste d’accueil INSERM). J.R., T.L.V., P.B. and Q.R. are supported by the Bettencourt-Schueller Foundation and the MD-PhD programme of Imagine Institute. P.B. was supported by the French Foundation for Medical Research (FRM, EA20170638020) and a ‘Poste CCA-INSERM-Bettencourt’ (with the support of the Fondation Bettencourt-Schueller). Q.P. was supported by the Assistance Publique Hôpitaux de Paris (AP-HP, Année Recherche) and the MD-PhD programme of INSERM (Ecole de l’INSERM Liliane Bettencourt). M.O. was supported by the David Rockefeller Graduate Program, the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), the New York Hideyo Noguchi Memorial Society (HNMS). Nils Landegren is funded by The Swedish Research Council and the Göran Gustafsson Foundation. B. Keller is funded by Bundesministerium für Bildung und Forschung (GAIN 01GM1910A). Q.P.-H. is supported by the Swedish Research Council, and the Knut and Alice Wallenberg Foundation (KAW). F. Hauck was funded by the Else Kröner-Fresenius Stiftung (EKFS, 2017_A110) and the German Federal Ministry of Education and Research (BMBF, 01GM1910C). L.D.N. and H.C.S. are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. C.S.M. and S.G.T. are supported by Investigator Grants awarded by the National Health and Medical Research Council of Australia. CIRCA Investigators (A.P-C, A.S, L.D, D.S, M.W, A.K, C.S.M, C.C.G, P.E.G, S.G.T) are funded by grants awarded by the Jeffrey Modell Foundation and the John Brown Cook Foundation. M. Momenilandi was supported by ANRS, Maladies infectieuses émergentes (ECTZ173053). F.R.L. was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM) and by government grants managed by the Agence National de la Recherche as part of the ‘Investment for the Future’ programme (Institut Hospitalo-Universitaire Imagine, grant ANR-10-IAHU-01, Recherche HospitaloUniversitaire, grant ANR-18-RHUS-0010), the Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), the Agence National de la Recherche (ANR-14-CE14-0026-01 ‘Lumugene’; ANR-18-CE17-0001 ‘Action’; ANR-22-CE15-0047-02 ‘BREAK-ITP’), the Fondation pour la recherche Médicale (FRM : EQU202103012670). F. Atschekzei was funded by the German Federal Ministry of Education and Research (BMBF, 01GM2206B) and the German Center for Infection Research (DZIF TTU 07.801)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul
  • Gervais, Adrian
  • Taniguchi, Maki
  • Saare, Liisa
  • Särekannu, Karita
  • Voyer, Tom Le
  • Philippot, Quentin
  • Rosain, Jérémie
  • Bizien, Lucy
  • Asano, Takaki
  • Garcia-Prat, Marina
  • Parra-Martínez, Alba
  • Migaud, Mélanie
  • Tsumura, Miyuki
  • Conti, Francesca
  • Belot, Alexandre
  • Rivière, Jacques G.
  • Morio, Tomohiro
  • Tanaka, Junko
  • Javouhey, Etienne
  • Haerynck, Filomeen
  • Duvlis, Sotirija
  • Ozcelik, Tayfun
  • Keles, Sevgi
  • Tandjaoui-Lambiotte, Yacine
  • Escoda, Simon
  • Husain, Maya
  • Pan-Hammarström, Qiang
  • Pérez-Tur, Jordi
  • Planas, Anna M.
  • Hammarström, Lennart
  • Ahlijah, Gloria
  • Haidar, Anthony Abi
  • Soudee, Camille
  • Arseguel, Vincent
  • Abolhassani, Hassan
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Nukui, Yoko
  • Hayakawa, Seiichi
  • Chrousos, George P.
  • Michos, Athanasios
  • Tatsi, Elizabeth Barbara
  • Filippatos, Filippos
  • Rodriguez-Palmero, Agusti
  • Troya, Jesus
  • Tipu, Imran
  • Meyts, Isabelle
  • Roussel, Lucie
  • Ostrowski, Sisse Rye
  • Schidlowski, Laire
  • Prando, Carolina
  • Condino-Neto, Antonio
  • Cheikh, Nathalie
  • Bousfiha, Ahmed A.
  • Bakkouri, Jalila El
  • Peterson, Pärt
  • Pujol, Aurora
  • Lévy, Romain
  • Quartier, Pierre
  • Vinh, Donald C.
  • Boisson, Bertrand
  • Béziat, Vivien
  • Zhang, Shen Ying
  • Borghesi, Alessandro
  • Pession, Andrea
  • Andreakos, Evangelos
  • Marr, Nico
  • Mentis, Alexios Fotios A.
  • Mogensen, Trine H.
  • Rodríguez-Gallego, Carlos
  • Soler-Palacin, Pere
  • Colobran, Roger
  • Tillmann, Vallo
  • Neven, Bénédicte
  • Trouillet-Assant, Sophie
  • Brodin, Petter
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Zhang, Qian
  • Martinón-Torres, Federico
  • Salas, Antonio
  • Gómez-Carballa, Alberto
  • Gonzalez-Granado, Luis I.
  • Kisand, Kai
  • Okada, Satoshi
  • Puel, Anne
  • Cobat, Aurélie
  • Casanova, Jean-Laurent
  • Aguilera-Albesa, Sergio
  • Alkhater, Suzan A.
  • Alkan, Gulsum
  • Castagnoli, Riccardo
  • Cyrus, Cyril
  • Bozdemir, Sefika Elmas
  • Emiroglu, Melike
  • Gulhan, Belgin
  • Erdeniz, Emine Hafize
  • Hatipoglu, Nevin
  • Bayhan, Gülsün Iclal
  • Jabandziev, Petr
  • Yuksek, Saliha Kanik
  • COVID Human Genetic Effort
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364, R01AI163029, and R21AI160576), the National Center for Advancing Translational Sciences, the NIH Clinical and Translational Science Award program (UL1TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the Stavros Niarchos Foundation Institute for Global Infectious Disease Research, the program “Investissement d’Avenir” launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRSCOV05, ANR GENVIR (ANR-20-CE93-003), ANR AI2D (ANR-22- CE15-0046), and ANR AAILC (ANR-21-LIBA-0002) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU COVIFERON Program (ANR-21-RHUS-08), the Square Foundation, Grandir - Fonds de solidarite pour l ´ ’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Sante et de la Recherche M ´ edicale (IN- ´ SERM), REACTing-INSERM, the University of Paris Cite and ´ Imagine Institute, Battersea & Bowery Advisory Group, and William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of Business in EMEA, and the General Atlantic Foundation. I. Meyts is a senior clinical researcher at FWO Vlaanderen; I. Meyts is funded by the European Research Council under HORIZON-HLTL-2021-ID: 101057100 "Undine," KU Leuven C16/18/007, and FWO grant G0B5120N (DADA2). L.D. Notarangelo and H.C. Su (members of the COVID Human Genetic Effort) were supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. P. Bastard was supported by the French Foundation for Medical Research (FRM, EA20170638020). P. Bastard and T. Le Voyer were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). P. Bastard was supported by the “Poste CCA-INSERM-Bettencourt” (with the support of the Fondation Bettencourt-Schueller). S. Okada was supported by MEXT/JSPS KAKENHI (grant numbers 22H03041 and 22KK0113) and AMED (grant numbers JP21fk0108436 and JP22fk0108514). L.I. Gonzalez-Granado is supported by the Instituto de Salud Carlos III (ISCIII) through the project FIS-PI21/01642 and cofunded by the European Union. D.C. Vinh is supported by a Fonds de Recherche du Quebec - Sant ´ e, Senior Clinician-Scientist scholar award. ´ Q. Pan-Hammarstrom was funded by the Swedish Research ¨ Council, and the Knut and Alice Wallenberg Foundation. K. Kisand’s laboratory was funded by the Estonian Research Council grants PRG1117 and PRG1428. This study also received support from ISCIII (TRINEO: PI22/00162; DIAVIR: DTS19/00049; ResviOmics: PI19/01039 [A. Salas]; ReSVinext: PI16/01569 [F. Martinón-Torres]; Enterogen: PI19/01090 [F. Martinón-Torres]); OMI-COVI-VAC (PI22/00406 [F. Martinón-Torres] jointly financed by FEDER), GAIN: Grupos con Potencial de Crecimiento (IN607B 2020/08 [A. Salas]); ACIS: BI-BACVIR (PRIS-3 [A. Salas]), and CovidPhy (SA 304 C [A. Salas]); and consorcio Centro de Investigación Biomedica en Red de Enfermedades Respira- ´ torias (CB21/06/00103; F. Martinón-Torres); GEN-COVID (IN845D 2020/23, F. Martinón-Torres) and Grupos de Referencia Competitiva (IIN607A2021/05, F. Martinón-Torres). The study was funded by ISCIII (COV20_01333, COV20_01334, PI16/ 00759, PI18/00223, PI19/00208, PI20/00876, and PI21/00211), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/ FEDER, EU), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43, PIFIISC22/27), Grupo DISA (OA18/017), Fundación MAPFRE Guanarteme (OA21/131), Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas cient´ıficas del ITER para colaborar en la lucha contra la COVID-19”). A. Pujol is supported by ACCI20-759 CIBERER, H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021- ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. This research is supported by the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases. Open Access funding provided by Rockefeller University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

  • Asano, Takaki
  • Boisson, Bertrand
  • Onodi, Fanny
  • Matuozzo, Daniela
  • Moncada-Velez, Marcela
  • Maglorius Renkilaraj, Majistor Raj Luxman
  • Zhang, Peng
  • Meertens, Laurent
  • Bolze, Alexandre
  • Materna, Marie
  • Korniotis, Sarantis
  • Gervais, Adrian
  • Talouarn, Estelle
  • Bigio, Benedetta
  • Seeleuthner, Yoann
  • Bilguvar, Kaya
  • Zhang, Yu
  • Neehus, Anna-Lena
  • Ogishi, Masato
  • Pelham, Simon J.
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Soler-Palacín, Pere
  • Colobran, Roger
  • Martin-Nalda, Andrea
  • Rivière, Jacques G.
  • Tandjaoui-Lambiotte, Yacine
  • Chaïbi, Khalil
  • Shahrooei, Mohammad
  • Darazam, Ilad Alavi
  • Olyaei, Nasrin Alipour
  • Mansouri, Davood
  • Hatipoğlu, Nevin
  • Palabiyik, Figen
  • Ozcelik, Tayfun
  • Novelli, Giuseppe
  • Novelli, Antonio
  • Casari, Giorgio
  • Aiuti, Alessandro
  • Carrera, Paola
  • Bondesan, Simone
  • Barzaghi, Federica
  • Rovere-Querini, Patrizia
  • Tresoldi, Cristina
  • Franco, Jose Luis
  • Rojas, Julian
  • Reyes, Luis Felipe
  • Bustos, Ingrid G.
  • Arias, Andres Augusto
  • Morelle, Guillaume
  • Christèle, Kyheng
  • Troya, Jesús
  • Planas-Serra, Laura
  • Schlüter, Agatha
  • Gut, Marta
  • Pujol, Aurora
  • Allende, Luis M.
  • Rodriguez-Gallego, Carlos
  • Flores, Carlos
  • Cabrera-Marante, Oscar
  • Pleguezuelo, Daniel E.
  • Pérez de Diego, Rebeca
  • Keles, Sevgi
  • Aytekin, Gokhan
  • Akcan, Ozge Metin
  • Bryceson, Yenan T.
  • Bergman, Peter
  • Brodin, Petter
  • Smole, Daniel
  • Smith, C. I. Edvard
  • Norlin, Anna-Carin
  • Campbell, Tessa M.
  • Covill, Laura E.
  • Hammarström, Lennart
  • Pan-Hammarström, Qiang
  • Abolhassani, Hassan
  • Mane, Shrikant
  • Marr, Nico
  • Ata, Manar
  • Al Ali, Fatima
  • Khan, Taushif
  • Spaan, András N.
  • Dalgard, Clifton L.
  • Bonfanti, Paolo
  • Biondi, Andrea
  • Tubiana, Sarah
  • Burdet, Charles
  • Nussbaum, Robert
  • Kahn-Kirby, Amanda
  • Snow, Andrew L.
  • Bustamante, Jacinta
  • Puel, Anne
  • Boisson-Dupuis, Stéphanie
  • Zhang, Shen-Ying
  • Béziat, Vivien
  • Lifton, Richard P.
  • Bastard, Paul
  • Notarangelo, Luigi D.
  • Abel, Laurent
  • Su, Helen C.
  • Jouanguy, Emmanuelle
  • Amara, Ali
  • Soumelis, Vassili
  • Cobat, Aurélie
  • Zhang, Qian
  • Casanova, Jean-Laurent
Members of COVID Human Genetic Effort: Laurent Abel1, Alessandro Aiuti2, Saleh Al-Muhsen3, Fahd Al-Mulla4, Mark S. Anderson5, Evangelos Andreakos6, Andrés A. Arias7, Hagit Baris Feldman8, Alexandre Belot9, Catherine M. Biggs10, Dusan Bogunovic11, Alexandre Bolze12, Anastasiia Bondarenko13, Ahmed A. Bousfiha14, Petter Brodin15, Yenan Bryceson16, Carlos D. Bustamante17, Manish J. Butte18, Giorgio Casari19, Samya Chakravorty20, John Christodoulou21, Antonio Condino-Neto22, Stefan N. Constantinescu23, Megan A. Cooper24, Clifton L. Dalgard25, Murkesh Desai26, Beth A. Drolet27, Jamila El Baghdadi28, Sara Espinosa-Padilla29, Jacques Fellay30, Carlos Flores31, José Luis Franco7, Antoine Froidure32, Peter K. Gregersen33, Filomeen Haerynck34, David Hagin35, Rabih Halwani36, Lennart Hammarström37, James R. Heath38, Sarah E. Henrickson39, Elena W. Y. Hsieh40, Eystein Husebye41, Kohsuke Imai42, Yuval Itan43, Erich D. Jarvis44, Timokratis Karamitros45, Kai Kisand46, Cheng-Lung Ku47, Yu-Lung Lau48, Yun Ling49, Carrie L. Lucas50, Tom Maniatis51, Davood Mansouri52, László Maródi53, Isabelle Meyts54, Joshua D. Milner55, Kristina Mironska56, Trine H. Mogensen57, Tomohiro Morio58, Lisa F. P. Ng59, Luigi D. Notarangelo60, Antonio Novelli61, Giuseppe Novelli62, Cliona O’Farrelly63, Satoshi Okada64, Tayfun Ozcelik65, Qiang Pan-Hammarström37, Rebeca Perez de Diego66, Anna M. Planas67, Carolina Prando68, Aurora Pujol69, Lluis Quintana-Murci70, Laurent Renia59, Igor Resnick71, Carlos Rodríguez-Gallego72, Vanessa Sancho-Shimizu73, Anna Sediva74, Mikko R. J. Seppänen75, Mohammed Shahrooei76, Anna Shcherbina77, Ondrej Slaby78, Andrew L. Snow79, Pere Soler-Palacín80, András N. Spaan81, Ivan Tancevski82, Stuart G. Tangye83, Ahmad Abou Tayoun84, Sathishkumar Ramaswamy84, Stuart E. Turvey85, Furkan Uddin86, Mohammed J. Uddin87, Diederik van de Beek88, Donald C. Vinh89, Horst von Bernuth90, Mayana Zatz91, Pawel Zawadzki92, Helen C. Su60, Jean-Laurent Casanova93, Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10-5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4 We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7 The patients' blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, Rockefeller University; the St. Giles Foundation; the NIH (R01AI088364), the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866); a Fast Grant from Emergent Ventures; Mercatus Center at the George Mason University; the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956); the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01) and the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (EQU201903007798); the FRM and ANR GENCOVID project, the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AABIFNCOV (ANR-20-CO11-0001) projects; the European Union’s Horizon 2020 Research and Innovation Program under grant agreement no. 824110 (EASI-genomics); the Square Foundation; Grandir–Fonds de solidarité pour l’enfance; the SCOR Corporate Foundation for Science; Fondation du Souffle; Institut National de la Santé et de la Recherche Médicale (INSERM); REACTing-INSERM; and the University of Paris. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). The Neurometabolic Diseases Laboratory received funding from the European Union’s Horizon 2020 Research and Innovation Program (EasiGenomics grant no. 824110 COVID-19/PID12342). A.P., R.P.d.D., C.R.-G., and C.F. were funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación DISA (OA18/017), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The laboratories of G.N. and A.N. were supported by a grant awarded to Regione Lazio (PROGETTI DI GRUPPI DI RICERCA 2020) no. A0375-2020-36663, GecoBiomark. A. Amara’s laboratory was supported by ANR under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the FRM (EQU202003010193), ANR (ANR-20-COVI-000 project IDISCOVR and ANR-20-CO11-0004 project FISHBP), and the University of Paris (Plan de Soutien Covid-19: RACPL20FIR01-COVIDSOUL). This work was supported, in part, by the Division of Intramural Research, NIAID, NIH (grants 1ZIAAI001265 to H.C.S. and ZIA AI001270 to L.D.N.). The G.C. laboratory was supported by the Italian Ministry of Health (grant COVID-2020-12371617) and the intramural COVID Host Genetics program. The J.L.F. laboratory was supported, in part, by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX; 806-2018) and Colciencias contract 713-2016 (no. 111574455633). The V.S. laboratory was supported by ANR DENDRISEPSIS (ANR-17-CE15-0003) and ANR APCOD (ANR-17-CE15-0003-01), a Fast Grant from the Mercatus Center, FRM, University of Paris PLAN D’URGENCE COVID19. The N.M. laboratory was supported by Sidra Medicine (SDR400048) and the Qatar National Research Fund (grant No. NPRP9-251-3-045). A.-L.N. was supported by the Bettencourt Schueller Foundation and the International PhD program of the Imagine Institute. P. Bergman and C.I.E.S received support from the Center for Medical Innovation (CIMED), the Swedish Medical Research Council and the Stockholm County Council (ALF-project). Part of this work was generated within the European Reference Network for rare primary immunodeficiency, autoinflammatory and autoimmune diseases (RITA). Author contributions: A.K.-K., A. Amara, A.C., A.G., A.-L.N., A. Puel, B. Boisson, E.J., F.A.A., F.O., J.B., J. Rosain, L.M., M.A., M.M.-V., M.M., M.O., M.R.L.M.R., N.M., P. Bastard, Q.P., Q.Z., S.B.-D., S.J.P., S. Korniotis, S.M., T.A., T.K., T.L.V., V.B., V.S., P.Z., S.-Y.Z., and Y.Z. performed or supervised experiments, generated and analyzed data, and contributed to the manuscript by providing figures and tables. A.C., A. Bolze, A. Pujol, B. Bigio, D. Matuozzo, K.B., L.A., and Y.S. performed computational analyses of data. A. Aiuti, A.A.A., A. Biondi, A.-C.N., A.L.S., A.M.-N., A.N., A.N.S., A.S., A. Pujol, C.B., C.F., C.K., C.L.D., C.T., D.E.P., D. Mansouri, D.S., E.J., C.I.E.S., F.B., F.P., G.A., G.C., G.M., G.N., H.A., H.C.S., I.A.D., I.G.B., J.C.R.G., J.G.R., J.L.F., J. Rojas, J.T., K.C., L.F.R., L.E.C., L.H., L.D.N., L.P.-S., M.G., L.M.A., M.S., N.A.O., N.H., O.C.-M., O.M.A., P. Bergman, P. Brodin, P.C., P.R.-Q., P.S.-P., P. Bastard, P. Bonfanti, Q.P.-H., Q.Z., R.C., R.N., R.P.d.D., R.P.L., S.A., S.B., S.T., S. Keles, T.M.C., T.O., Y.T.B., and Y.T.-L. evaluated and recruited patients to the COVID and/or control cohorts. B. Boisson, Q.Z., A.C., L.A. and J.-L.C. wrote the manuscript. All the authors edited the manuscript. J.-L.C. supervised the project, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Transportome remodeling of a symbiotic microalga inside a planktonic host

  • Juéry, Caroline
  • Auladell, Adria
  • Füssy, Zoltan
  • Chevalier, Fabien
  • Yee, Daniel P.
  • Pelletier, Eric
  • Corre, Erwan
  • Allen, Andrew E.
  • Richter, Daniel J.
  • Decelle, Johan
Metabolic exchange is one of the foundations of symbiotic associations between organisms and is a driving force in evolution. In the ocean, photosymbiosis between heterotrophic hosts and microalgae is powered by photosynthesis and relies on the transfer of organic carbon to the host (e.g. sugars). Yet, the identity of transferred carbohydrates as well as the molecular mechanisms that drive this exchange remain largely unknown, especially in unicellular photosymbioses that are widespread in the open ocean. Combining genomics, single-holobiont transcriptomics, and environmental metatranscriptomics, we revealed the transportome of the marine microalga Phaeocystis in symbiosis within acantharia, with a focus on sugar transporters. At the genomic level, the sugar transportome of Phaeocystis is comparable to non-symbiotic haptophytes. By contrast, we found significant remodeling of the expression of the transportome in symbiotic microalgae compared to the free-living stage. More particularly, 36% of sugar transporter genes were differentially expressed. Several of them, such as GLUTs, TPTs, and aquaporins, with glucose, triose-phosphate sugars, and glycerol as potential substrates, were upregulated at the holobiont and community level. We also showed that algal sugar transporter genes exhibit distinct temporal expression patterns during the day. This reprogramed transportome indicates that symbiosis has a major impact on sugar fluxes within and outside the algal cell, and highlights the complexity and the dynamics of metabolic exchanges between partners. This study improves our understanding of the molecular players of the metabolic connectivity underlying the ecological success of planktonic photosymbiosis and paves the way for more studies on transporters across photosymbiotic models., Research was supported by CNRS and ATIP-Avenir program funding, and by the European Union (BIOcean5D—GA#101059915 and ERC—SymbiOCEAN—101088661). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 for the sequencing (EASI Genomics). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 for the sequencing (EASI Genomics). Z.F. and A.A. were funded by National Oceanic and Atmospheric Administration grant NA19NOS4780181 (to A.E.A.), the National Science Foundation (NSF-OCE-1756884 to A.E.A.), and the Simons Collaboration on Principles of Microbial Ecosystems (PriME; grant ID: 970820 to A.E.A.). Their work (proposal: 10.46936/10.25585/60001426) conducted in the US Department of Energy Joint Genome Institute (https://ror.org/04xm1d337), a DOE Office of Science User Facility, is supported by the Office of Science of the US Department of Energy operated under contract no. DE-AC02-05CH11231. A.A. and D.J.R. received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement 949745—GROWCEAN—ERC-2020-STG) and from the Departament de Recerca i Universitats de la Generalitat de Catalunya (exp. 2021 SGR 00751)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2

  • DeDiego, Marta L.
  • López-Fernández-Sobrino, Raúl
  • Pedragosa, Jordi
  • López-García, Darío
  • Nogales, Aitor
  • Durbán, Jordi
  • Cardona, Fernando
  • Llucià-Carol, Laia
  • Rivero, Vanessa
  • Vázquez-Utrilla, Paula
  • Sanchez-Grande, Laura Palomo
  • Cobo Cano, Miriam
  • Lloret Iglesias, Lara
  • Márquez-Kisinousky, Leonardo
  • Ruíz-Jaén, Francisca
  • Rojo, Silvia
  • Fiz-López, Aida
  • Arribas, Elisa
  • Cal-Sabater, Paloma de la
  • Bernardo, David
  • Pérez-Tur, Jordi
  • COVID Human Genetic Effort
COVID Human Genetic Effort: et al., Recessive deficiency in 2′,5′-oligoadenylate synthetase (OAS) or RNase L can cause systemic inflammation in children with SARS-CoV-2 infection, but its role in adult respiratory disease is unclear. We analyzed rare OAS1/OAS3 variants and the common OAS1 rs10774671 polymorphism in 342 COVID-19 patients, assessing enzymatic activity, RNase L activation, viral replication, and inflammation in cell systems and Oas3-deficient mice. Rare heterozygous variants showed impaired RNase L activation but were not enriched in pneumonia cases. In contrast, the rs10774671 A/A genotype (OAS1-p42 isoform) was associated with severe disease (OR = 2.28; 95% CI = 1.13–4.58; p = 0.0107) and reduced viral control despite intact RNase L activation. OAS3 and OAS1-p46 isoform limited viral replication and inflammatory responses, whereas Oas3-deficient mice showed increased cytokines. These findings suggest that common OAS1 variation influences COVID-19 severity, while rare OAS variants may affect inflammation regulation rather than respiratory pathology., Supported by the Spanish National Research Council (CSIC) through the Fondo COVID-19 (Ref. CSIC-202020E086). This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). Funds were also provided by the Spanish Ministry of Science and Innovation, PID2021-123810OB-I00 funded by MCIN/AEI/10.13039/50110.00110.33 and CNS2022-135276. We acknowledge the EASI-Genomics initiative (PID12396) that received funds from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuronal type-specific modulation of cognition and AP-1 signaling by early-life rearing conditions

  • Alaiz-Noya, Marta
  • Miozzo, Federico
  • Fuentes-Ramos, Miguel
  • Machnicka, Magdalena A.
  • Kurowska, Marcelina
  • Herrera, Macarena
  • Blanco, Beatriz del
  • Niñerola, Sergio
  • Bustos-Martínez, Isabel
  • Wilczynski, Bartek
  • Barco, Ángel
Environmental conditions profoundly influence cognitive development, particularly during early life. Transcriptional and epigenetic mechanisms may serve as molecular substrates for the lasting effects of environmental enrichment (EE) and impoverishment (IE) on cognitive abilities and hippocampal function. However, the specific gene programs driving these changes remain largely unknown. In this study using female mice, EE and IE produced opposite effects on cognitive performance. By combining hippocampal microdissection and genetic tagging of neuronal nuclei with genome-wide analyses of gene expression, chromatin accessibility, histone acetylation, and DNA methylation, we uncovered profound differences in the transcriptional and epigenetic profiles of CA1 pyramidal neurons and dentate gyrus (DG) granule neurons. These analyses revealed cell type-specific genomic changes induced by EE and IE, highlighting distinct patterns of neuroadaptation within each population. This multiomic screen pinpointed the activity-regulated transcription factor AP-1 as a crucial mediator of neuroadaptation to conditions during early life in both cell types, albeit through distinct downstream mechanisms. Conditional deletion of Fos, a core AP-1 subunit, in excitatory neurons hampered EE-induced cognitive enhancement, further underscoring the pivotal role of this transcription factor in neuroadaptation., We thank Anne-Laurence Boutillier, Jose Vicente Sanchez-Mut and Rafael Alcala-Vida for critical reading of the manuscript. We thank the personnel of the Mouse facility and the Microscopy and Omics core services at the Instituto de Neurociencias for their assistance. We also thank the collaboration of A. Medrano-Fernandez and J. Medrano-Relinque in preliminary experiments and R. Olivares and C. Racovac for technical assistance. M.A-N. was recipient of a fellowship from Generalitat Valenciana. M.F-R. was recipient of a FPU fellowship from the Spanish Ministry of Education. I.B-M. and S.N. are recipients of fellowships from the Spanish Ministry of Science and Innovation (MICINN). A.B. research is supported by grants FCAIXA HR22-00394 from Fundación LaCaixa, PID2020-118169RB-I00 and PID2023-148442NB-I00 from AEI co-financed by ERDF, AC22-00030/JPND2022-115 from ISCIII and CIPROM/2023/15 from the Generalitat Valenciana. B.W. is supported by the JPco-fuND2 Program (2022/04/Y/NZ2/00116) from the National Science Centre, Poland. WGBS experiments were performed in collaboration with the DKFZ sequencing facility and received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-Genomics). The Instituto de Neurociencias is a “Centre of Excellence Severo Ochoa” (CEX2021-001165-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity

  • Al Qureshah, Fahd
  • COVID-19 HGE Consortium members
  • Pérez-Tur, Jordi
  • Casanova, Jean-Laurent
34 páginas, 7 figuras, 1 tabla. Anexada lista completa de autores del COVID-19 HGE Consortium members, Autosomal recessive deficiency of the IFNAR1 or IFNAR2 chain of the human type I IFN receptor abolishes cellular responses to IFN-α, -β, and -ω, underlies severe viral diseases, and is globally very rare, except for IFNAR1 and IFNAR2 deficiency in Western Polynesia and the Arctic, respectively. We report 11 human IFNAR1 alleles, the products of which impair but do not abolish responses to IFN-α and -ω without affecting responses to IFN-β. Ten of these alleles are rare in all populations studied, but the remaining allele (P335del) is common in Southern China (minor allele frequency ≈2%). Cells heterozygous for these variants display a dominant phenotype in vitro with impaired responses to IFN-α and -ω, but not -β, and viral susceptibility. Negative dominance, rather than haploinsufficiency, accounts for this dominance. Patients heterozygous for these variants are prone to viral diseases, attesting to both the dominance of these variants clinically and the importance of IFN-α and -ω for protective immunity against some viruses., This study was supported in part by the St. Giles Foundation; the Rockefeller University; the Howard Hughes Medical Institute; Institut National de la Sant´ e et de la Recherche M´ edicale (INSERM); the Imagine Institute; Paris Cit´ e University; the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the National Center for Research Resources; the National Center for Advancing Sciences of the National Institutes of Health (NIH) (UL1TR001866); NIH (R01AI163029); American Lung Association (COVID-1026207); Stavros Niarchos Foundation (SNF) as part of its grant to the SNF Institute for Global Infectious Disease Research at The Rockefeller University; the Square Foundation; Grandir- Fonds de solidarit´ epour l’enfance; theFondation du Souffle; the SCOR Corporate Foundation for Science; the Battersea and Bowery Advisory Group; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10IAHU-01); the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); ANR GENVIR(ANR-20-CE93-003);ANRAAILC(ANR-21-LIBA-0002); ANR AI2D (ANR-22-CE15-0046); ANR GENFLU (ANR-22-CE920004); the ANR-RHUCOVIFERONprogram(ANR-21-RHUS-08); the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE); the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics); W.E. Ford, General Atlantic’s Chairman and Chief Executive Officer, G. Caillaux, General Atlantic’s Co-President, Managing Director and Head of Business in EMEA, and the General Atlantic Foundation; the French Ministry of Higher Education, Research, and Innovation (MESRICOVID-19); REACTing-INSERM. SEAe Consortium was supported by ANR SEA host factors (ANR-18-CE15-0020-01), Institut Pasteur, Institut Pasteur International Network, Fondation M´ erieux, Aviesan Sud, INSERM, Wellcome Trust, Institut de Recherche pour le D´ eveloppement (IRD), and Fondation Total. F. Al Qureshah was funded by the Ibn Rushd Postdoctoral Fellowship by King Abdullah University of Science and Technology (KAUST), and by the King Abdulaziz City for Science and Technology (KACST). P. Bastard was supported by the FRM (EA20170638020), the MD-PhD program of the Imagine Institute (with support from the Fondation Bettencourt-Schueller), and a “Poste CCA-INSERMBettencourt” (with support from the Fondation BettencourtSchueller). Y.L. Lau was supported by the Hong Kong Society for the Relief of Disabled Children for his research on inborn errors of immunity. R. Halwani was supported by the Deanship of Scientific Research, King Saud University, and funded through the Vice Deanship of Scientific Research Chairs; Research Chair of Prince Abdullah Ben Khalid Celiac Disease; Riyadh, Kingdom of Saudi Arabia. F. Vianna was supported in part by the Coordenação de Aperfeiçoamento de Pessoal de N´ ıvel Superior- Brasil (CAPES)- Finance Code 001 and by the Conselho Nacional de Desenvolvimento Cient´ ıfico e Tecnológico (12960/2021-2). Open Access funding provided by Rockefeller University.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology

  • Stanley, Kate
  • Jatsenko, Tatjana
  • Tuveri, Stefania
  • Sudhakaran, Dhanya
  • Lannoo, Lore
  • Van Calsteren, Kristel
  • Toledo, Rodrigo
Cell-free DNA fragmentation; Cancer, Fragmentación de ADN libre de células; Cáncer, Fragmentació d'ADN lliure de cèl·lules; Càncer, Circulating cell-free DNA (cfDNA) fragments have characteristics that are specific to the cell types that release them. Current methods for cfDNA deconvolution typically use disease tailored marker selection in a limited number of bulk tissues or cell lines. Here, we utilize single cell transcriptome data as a comprehensive cellular reference set for disease-agnostic cfDNA cell-of-origin analysis. We correlate cfDNA-inferred nucleosome spacing with gene expression to rank the relative contribution of over 490 cell types to plasma cfDNA. In 744 healthy individuals and patients, we uncover cell type signatures in support of emerging disease paradigms in oncology and prenatal care. We train predictive models that can differentiate patients with colorectal cancer (84.7%), early-stage breast cancer (90.1%), multiple myeloma (AUC 95.0%), and preeclampsia (88.3%) from matched controls. Importantly, our approach performs well in ultra-low coverage cfDNA datasets and can be readily transferred to diverse clinical settings for the expansion of liquid biopsy., We would like to thank the patients and their families for agreeing to participate in this study. We would like to thank the Genomics Core at KU Leuven for the use of the sequencing facilities. Funding was received from the European Union’s Horizon 2020 research and innovation program under grant agreement No 824110 – EASI-Genomics (J.R.V.) and the Marie Skłodowska-Curie grant agreement No 813707 (MATER), from Kom Op Tegen Kanker (Stand up to Cancer) KOTK/2018/11468, from the Flemish cancer society (2016/10728/2603 to A.C.), and FWO-SBO grant S003422N, and from Agentschap Innoveren en Ondernemen (VLAIO; Flanders Innovation & Entrepreneurship grant HBC.2018.2108). S.T. was supported by FWO SB/1S74420N. Institutional support was received from the KU Leuven, C1- C14/18/092, C14/22/125, and C3/20/100 to J.R.V
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

  • Asano, Takaki
  • Boisson, Bertrand
  • Onodi, Fanny
  • Matuozzo, Daniela
  • Moncada Velez, Marcela
  • Maglorius Renkilaraj, Majistor Raj Luxman
  • Zhang, Peng
  • Meertens, Laurent
  • Bolze, Alexandre
  • Materna, Marie
  • Korniotis, Sarantis
  • Khan, Taushif
  • Spaan, András N.
  • Bonfanti, Paolo
  • Tubiana, Sarah
  • Burdet, Charles
  • Nussbaum, Robert L.
  • Kahn-Kirby, Amanda
  • Snow, Andrew L.
  • Bustamante, Jacinta
  • Puel, Anne
  • Lifton, Richard P.
  • Boisson-Dupuis, Stéphanie
  • Notarangelo, Luigi D.
  • Zhang, Shen-Ying
  • Su, Helen C.
  • Béziat, Vivien
  • Bastard, Paul
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Amara, Ali
  • Soumelis, Vassili
  • Cobat, Aurélie
  • Zhang, Qian
  • Casanova, Jean-Laurent
  • COVID Human Genetic Effort
  • French COVID Cohort Study Group
  • COVID-STORM Clinicians
  • Amsterdam UMC Covid-19 Biobank
  • COVID Clinicians
  • Gervais, Adrian
  • Imagine COVID Group
  • CoV-Contact Cohort
  • NIAID-USUHS COVID Study Group
  • Talouarn, Estelle
  • Bigio, Benedetta
  • Seeleuthner, Yoann
  • Bilguvar, Kaya
  • Zhang, Yu
  • Neehus, Anna-Lena
  • Ogishi, Masato
  • Soler-palacín, Pere
  • Pelham, Simon J.
  • Martin Nalda, Andrea
  • Le Voyer, Tom
  • Rosain, Jérémie
  • Philippot, Quentin
  • Colobran, Roger
  • Rivière, Jacques G.
  • Tandjaoui-Lambiotte, Yacine
  • Chaïbi, Khalil
  • Shahrooei, Mohammad
  • Darazam, Ilad Alavi
  • Olyaei, Nasrin Alipour
  • Mansouri, Davood
  • Hatipoğlu, Nevin
  • Casari, Giorgio
  • Palabiyik, Figen
  • Carrera, Paola
  • Ozcelik, Tayfun
  • Novelli, Giuseppe
  • Novelli, Antonio
  • Aiuti, Alessandro
  • Bondesan, Simone
  • Barzaghi, Federica
  • Rovere-Querini, Patrizia
  • Tresoldi, Cristina
  • Franco, Jose Luis
  • Rojas, Julian
  • Reyes, Luis Felipe
  • Bustos, Ingrid G.
  • Planas Serra, Laura
  • Arias, Andres Augusto
  • Gut, Marta
  • Morelle, Guillaume
  • Christèle, Kyheng
  • Troya, Jesús
  • Schlüter, Agatha
  • Pujol, Aurora, 1968-
  • Allende, Luis M.
  • Rodriguez Gallego, Carlos
  • Flores, Carlos
  • Cabrera Marante, Oscar
  • Pleguezuelo, Daniel E.
  • Pérez de Diego, Rebeca
  • Keles, Sevgi
  • Brodin, Petter
  • Aytekin, Gokhan
  • Smith, C.I. Edvard
  • Akcan, Ozge Metin
  • Bryceson, Yenan T.
  • Bergman, Peter
  • Smole, Daniel
  • Norlin, Anna-Carin
  • Campbell, Tessa M.
  • Covill, Laura E.
  • Hammarström, Lennart
  • Pan-Hammarström, Qiang
  • Abolhassani, Hassan
  • Mane, Shrikant
  • Marr, Nico
  • Dalgard, Clifton L.
  • Ata, Manar
  • Biondi, Andrea
  • Al Ali, Fatima
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10-5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4 We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7 The patients' blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inborn errors of type I IFN immunity in patients

  • Zhang, Qian
  • Gut, Marta
  • Casanova, Jean-Laurent
Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection., This work was supported by a generous donation from the Fisher Center for Alzheimer’s Research Foundation. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the NIH (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project, ANRS-COV05, the Square Foundation, Grandir–Fonds de Solidarité pour l’Enfance, the SCOR Corporate Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM), the University of Paris. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”), and the Intramural Research Program of the NIAID, NIH. The laboratory of Genomes & Cell Biology of Disease is supported by “Integrative Biology of Emerging Infectious Diseases” (grant no. ANR-10-LABX-62-IBEID), the “Fondation pour la Recherche Medicale” (grant FRM–EQU202003010193), the “Agence Nationale de la Recherche” (ANR FLASH COVID project IDISCOVR cofounded by the “Fondation pour la Recherche Médicale”), University of Paris (“Plan de Soutien Covid-19”: RACPL20FIR01-COVID-SOUL). I.M. is a senior clinical investigator with the FWO Vlaanderen; I.M. and L.M. are supported by FWO G0C8517N – GOB5120N. The VS team was supported by “Agence Nationale de la Recherche” (ANR-17-CE15-0003, ANR-17-CE15-0003-01) and by Université de Paris “PLAN D’URGENCE COVID19”. L.K. was supported by a fellowship from the French Ministry of Research. V.S.-S. is supported by a UKRI Future Leaders Fellowship (MR/S032304/1). S.Z.A.-M. is supported by the Elite Journals Program at King Saud University through grant no. PEJP-16-107. The J.M. laboratory is supported by Columbia University COVID biobank and grant no. UL1TR001873. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1; a George Mason University Fast Grant; and the G. Harold and Leila Y. Mathers Charitable Foundation. J.L.P. is supported by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018). Work at the Neurometabolic Diseases Laboratory received funding from the European Union’s Horizon 2020 research and innovation program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342) to A.P., and Roche and Illumina Covid Match Funds to M.G.. C.R.G. and colleagues are supported by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), Spanish Ministry of Science and Innovation, with the funding of European Regional Development Fund-European Social Fund -FEDER-FSE; (RTC-2017-6471-1; AEI/FEDER, UE), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). D.C.V. is supported by the Fonds de la recherche en santé du Québec clinician-scientist scholar program. H.S. is adjunct faculty at the University of Pennsylvania. A.-L.N. was supported by the Foundation Bettencourt Schueller. The Amsterdam UMC Covid-19 Biobank was funded by the Netherlands Organization for Health Research and Development (ZonMw, NWO-vici 91819627), The Corona Research Fund (Amsterdam UMC), Dr. J. C. Vaillantfonds, and Amsterdam UMC. Work on COVID-19 at the A.G.-S. laboratory is partly supported by NIH supplements to grants U19AI135972, U19AI142733, and R35 HL135834, and to contract HHSN272201800048C, by a DoD supplement to grant W81XWH-20-1-0270, by DARPA project HR0011-19-2-0020, by CRIP (Center for Research on Influenza Pathogenesis), a NIAID funded Center of Excellence for Influenza Research and Surveillance (CEIRS, contract HHSN272201400008C), by an NIAID funded Collaborative Influenza Vaccine Innovation Center (SEM-CIVIC, contract 75N93019C00051) and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611(5384)) and anonymous donors. The Virscan analysis presented in fig. S11 was performed with financial support from Sidra Medicine. J.R.H. is supported by Biomedical Advanced Research and Development Authority under Contract (HHSO10201600031C).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Framework for quality assessment of whole genome cancer sequences

  • Whalley, Justin P.
  • Stobbe, Miranda D.
  • Beltran, Sergi
  • Gut, Marta
  • Trotta, Jean-Remi
  • Gut, Ivo Glynne
Bringing together cancer genomes from different projects increases power and allows the investigation of pan-cancer, molecular mechanisms. However, working with whole genomes sequenced over several years in different sequencing centres requires a framework to compare the quality of these sequences. We used the Pan-Cancer Analysis of Whole Genomes cohort as a test case to construct such a framework. This cohort contains whole cancer genomes of 2832 donors from 18 sequencing centres. We developed a non-redundant set of five quality control (QC) measurements to establish a star rating system. These QC measures reflect known differences in sequencing protocol and provide a guide to downstream analyses and allow for exclusion of samples of poor quality. We have found that this is an effective framework of quality measures. The implementation of the framework is available at: https://dockstore.org/containers/quay.io/jwerner_dkfz/pancanqc:1.2.2., J.P.W., M.D.S., S.B., M.G., J.T. and I.G.G. acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme. We also acknowledge the support through the European Union’s Horizon 2020-funded project EASI-Genomics under grant agreement no 824110. The funding bodies did not have any influence on the design of the study and collection, analysis, and interpretation of data and in writing the paper.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A method for multiplexed full-length single-molecule sequencing of the human mitochondrial genome

  • Keraite, Ieva
  • Becker, Philipp
  • Canevazzi, Davide
  • Frías-López, Cristina
  • Dabad, Marc
  • Leno Colorado, Jorge
  • Abulí Vidal, Anna
  • García Arumí, Elena
  • Tonda, Raul
Data processing; DNA sequencing; Genomic analysis, Tratamiento de datos; Secuenciación de ADN; Análisis genómico, Tractament de dades; Seqüenciació d'ADN; Anàlisi genòmica, Methods to reconstruct the mitochondrial DNA (mtDNA) sequence using short-read sequencing come with an inherent bias due to amplification and mapping. They can fail to determine the phase of variants, to capture multiple deletions and to cover the mitochondrial genome evenly. Here we describe a method to target, multiplex and sequence at high coverage full-length human mitochondrial genomes as native single-molecules, utilizing the RNA-guided DNA endonuclease Cas9. Combining Cas9 induced breaks, that define the mtDNA beginning and end of the sequencing reads, as barcodes, we achieve high demultiplexing specificity and delineation of the full-length of the mtDNA, regardless of the structural variant pattern. The long-read sequencing data is analysed with a pipeline where our custom-developed software, baldur, efficiently detects single nucleotide heteroplasmy to below 1%, physically determines phase and can accurately disentangle complex deletions. Our workflow is a tool for studying mtDNA variation and will accelerate mitochondrial research., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 – EASI-Genomics (I.G.G.) and the ERC Synergy project BCLL@las under grant agreement No 810287 (I.G.G.). Institutional support was from the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias and cofunded with ERDF funds (PI19/01772). We acknowledge the institutional support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and institutional co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme to the institute.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths

  • Bastard, Paul
  • Gut, Marta
  • Casanova, Jean-Laurent
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS Nord-Sud (ANRS-COV05), ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-genomics), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM) and the University of Paris. PB was supported by the French Foundation for Medical Research (FRM, EA20170638020). PB, JR and TLV were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). Work in the Laboratory of Virology and Infectious Disease was supported by the NIH (P01AI138398-S1, 2U19AI111825, and R01AI091707-10S1), a George Mason University Fast Grant, and the G. Harold and Leila Y. Mathers Charitable Foundation. The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). This work was also partly supported by the Intramural Research Program of the NIAID and NIDCR, NIH (grants ZIA AI001270 to LDN and 1ZIAAI001265 to HCS). This program is supported by the Agence Nationale de la Recherche, reference ANR-10-LABX-69-01. K. Kisand’s group was supported by the Estonian Research Council grant PRG117 and PRG377. R. Halwani is supported by a grant from Al Jalila Foundation Seed Grant (AJF202019), Dubai, UAE, and a COVID-19 research grant (COV19-0307) from University of Sharjah, UAE. L. Imberti reported funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). L. Imberti and G.L. Marseglia reported funding from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbidità”). This research was partially supported by the Instituto de Salud Carlos III (COV20/0968). J. R. Heath reported funding from Biomedical Advanced Research and Development Authority HHSO10201600031C. S. Okada reports funding Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and development, AMED (Grant Number: JP20fk0108531). G. Gorochov was supported by ANR Flash COVID-19 program and SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs. The Three-City (3C) Study was conducted under a partnership agreement among the INSERM, the Victor Segalen–Bordeaux II University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study was also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme “Cohortes et collections de données biologiques”. S. Debette was supported by the University of Bordeaux Initiative of Excellence. P. K. Gregersen reports funding from the National Cancer Institute, NIH, under Contract No. 75N91019D00024, Task Order No. 75N91021F00001. J.W. is supported by an FWO Fundamental Clinical Mandate (1833317N). Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. Work at Vall d’Hebron was also partly supported by research funding from Instituto de Salud Carlos III grant PI17/00660 cofinanced by the European Regional Development Fund (ERDF). C.R.G. and colleagues of the Canarian Health System Sequencing Hub were supported by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334, Spanish Ministry of Science and Innovation RTC-2017-6471-1; AEI/FEDER, UE); from Grupo DISA (OA18/017 and OA20/024); and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). CMB is supported by a MSFHR Health Professional-Investigator Award. PQH and LH were funded by the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650). Work at Y.-L. Lau’s laboratory in the University of Hong Kong (HKU) was supported by the Society for the Relief of Disabled Children. MBBS/PhD study of D.L. Leung in HKU was supported by the Croucher Foundation. J.L.F. was supported in part by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX (806-2018) and Colciencias contract 713-2016 (code 111574455633). A.K. was in part supported by grants NU20-05-00282 and NV18-05-00162 issued by the Czech Health Research Council and Ministry of Health, Czech Republic. L.P. was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617). I.M. is a Senior Clinical Investigator at the Research Foundation – Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. IM has received funding under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 948959)”. E.A. received funding from the Hellenic Foundation for Research and Innovation (INTERFLU, no. 1574). M.V. received funding from the Sao Paulo Research Foundation (FAPESP) [grant number: 2020/09702-1] and JBS S.A [grant number 69004]. The NH-COVAIR was supported by a grant from the Meath Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children

  • Lee, Danyel
  • COVID Human Genetic Effort
  • Zhang, Shen-Ying
Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition that follows benign COVID-19. We report autosomal recessive deficiencies of OAS1, OAS2, or RNASEL in five unrelated children with MIS-C. The cytosolic double-stranded RNA (dsRNA)-sensing OAS1 and OAS2 generate 2'-5'-linked oligoadenylates (2-5A) that activate the single-stranded RNA-degrading ribonuclease L (RNase L). Monocytic cell lines and primary myeloid cells with OAS1, OAS2, or RNase L deficiencies produce excessive amounts of inflammatory cytokines upon dsRNA or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stimulation. Exogenous 2-5A suppresses cytokine production in OAS1-deficient but not RNase L-deficient cells. Cytokine production in RNase L-deficient cells is impaired by MDA5 or RIG-I deficiency and abolished by mitochondrial antiviral-signaling protein (MAVS) deficiency. Recessive OAS-RNase L deficiencies in these patients unleash the production of SARS-CoV-2-triggered, MAVS-mediated inflammatory cytokines by mononuclear phagocytes, thereby underlying MIS-C., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R21AI160576), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High-Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU Program ANR-21-RHUS-08 (COVIFERON), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), and Paris Cité University. We acknowledge support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH under award R01AI104887 to R.H.S. and S.R.W. The Laboratory of Human Evolutionary Genetics (Institut Pasteur) is supported by the Institut Pasteur, the Collège de France, the French Government’s Investissement d’Avenir program, Laboratoires d’Excellence “Integrative Biology of Emerging Infectious Diseases” (ANR-10-LABX-62-IBEID) and “Milieu Intérieur” (ANR-10-LABX-69-01), the Fondation de France (no. 00106080), the FRM (Equipe FRM DEQ20180339214 team), and the ANR COVID-19-POPCELL (ANR-21-CO14-0003-01). A.Puj. is supported by ACCI20-759 CIBERER, EasiGenomics H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021-ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. The Canarian Health System sequencing hub was funded by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación MAPFRE Guanarteme (OA21/131), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The CoV-Contact Cohort was funded by the French Ministry of Health and the European Commission (RECOVER project). Our studies are also funded by the Ministry of Health of the Czech Republic Conceptual Development of Research Organization (FNBr, 65269705) and ANID COVID0999 funding in Chile. G. Novelli and A. Novelli are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark. A.M.P., M.L.D., and J.P.-T. are supported by the Inmungen-CoV2 project of CSIC. This work was supported in part by the Intramural Research Program of the NIAID, NIH. The research work of A.M..P, M.L.D., and J.P.-T. was funded by the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). I.M. is a senior clinical investigator at FWO Vlaanderen supported by a VIB GC PID grant, by FWO grants G0B5120N (DADA2) and G0E8420N, and by the Jeffrey Modell Foundation. I.M. holds an ERC-StG MORE2ADA2 grant and is also supported by ERN-RITA.​ A.Y. is supported by fellowships from the European Academy of Dermatology and Venereology and the Swiss National Science Foundation and by an Early Career Award from the Thrasher Research Fund. Y.-H.C. is supported by an A*STAR International Fellowship (AIF). M.O. was supported by the David Rockefeller Graduate Program, the New York Hideyo Noguchi Memorial Society (HNMS), the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the National Cancer Institute (NCI) F99 Award (F99CA274708). A.A.A. was supported by Ministerio de Ciencia Tecnología e Innovación MINCIENCIAS, Colombia (111584467551/CT 415-2020). D.L. is supported by a fellowship from the FRM for medical residents and fellows. E.H. received funding from the Bank of Montreal Chair of Pediatric Immunology, Foundation of CHU Sainte-Justine, CIHR grants PCC-466901 and MM1-181123, and a Canadian Pediatric Society IMPACT study. Q.P.-H. received funding from the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650), the Swedish Research Council, and the Knut and Alice Wallenberg Foundation. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, and R01AI161444; a George Mason University Fast Grant; the G. Harold and Leila Y. Mathers Charitable Foundation; the Meyer Foundation; and the Bawd Foundation. R.P.L. is on the board of directors of both Roche and the Roche subsidiary Genentech. J.L.P. was supported by a Francois Wallace Monahan Postdoctoral Fellowship at the Rockefeller University and by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

  • Marchal, Astrid
  • COVID Clinicians
  • Bolze, Alexandre
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer's Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (Equation 201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of business in EMEA, and the General Atlantic Foundation, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. A.N.S. is supported by European Union’s Horizon Health research and innovation program under grant agreement No. 101057100, project UNDINE. S.G.T. is supported by an Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a University of New South Wales Sydney COVID Rapid Response Initiative grant. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 10101616. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health and Fondation AP-HP Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0048). Y.Z. is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. This project has received funding from the Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959), the Swiss National Science Foundation (grant # 310030L_197721 to J.F.), and ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grants AJF202019 and AJF20259 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I. Erkizia, E. Grau, M. Massanella, and J. Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling, and processing.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Combining nanopore and illumina sequencing permits detailed analysis of insertion mutations and structural variations produced by PEG-Mediated transformation in ostreococcus tauri

  • Thomy, Julie
  • Sanchez, Frederic
  • Gut, Marta
  • Cruz, Fernando
  • Alioto, Tyler
  • Piganeau, Gwenael
  • Grimsley, Nigel
  • Yau, Sheree
Ostreococcus tauri is a simple unicellular green alga representing an ecologically important group of phytoplankton in oceans worldwide. Modern molecular techniques must be developed in order to understand the mechanisms that permit adaptation of microalgae to their environment. We present for the first time in O. tauri a detailed characterization of individual genomic integration events of foreign DNA of plasmid origin after PEG-mediated transformation. Vector integration occurred randomly at a single locus in the genome and mainly as a single copy. Thus, we confirmed the utility of this technique for insertional mutagenesis. While the mechanism of double-stranded DNA repair in the O. tauri model remains to be elucidated, we clearly demonstrate by genome resequencing that the integration of the vector leads to frequent structural variations (deletions/insertions and duplications) and some chromosomal rearrangements in the genome at the insertion loci. Furthermore, we often observed variations in the vector sequence itself. From these observations, we speculate that a nonhomologous end-joining-like mechanism is employed during random insertion events, as described in plants and other freshwater algal models. PEG-mediated transformation is therefore a promising molecular biology tool, not only for functional genomic studies, but also for biotechnological research in this ecologically important marine alga., This research received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 824110—EASI-Genomics and the French National Research Agency project grant (ANR Algalvirus ANR-17-CE02-0012). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and cofinancing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

  • Asano, Takaki
  • Gut, Marta
  • Casanova, Jean-Laurent
Autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptomatically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10-5). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10-4 We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7 The patients' blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract., Funding: The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, Rockefeller University; the St. Giles Foundation; the NIH (R01AI088364), the National Center for Advancing Translational Sciences (NCATS); NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866); a Fast Grant from Emergent Ventures; Mercatus Center at the George Mason University; the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956); the Meyer Foundation; the JPB Foundation; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01) and the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); the French Foundation for Medical Research (FRM) (EQU201903007798); the FRM and ANR GENCOVID project, the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AABIFNCOV (ANR-20-CO11-0001) projects; the European Union’s Horizon 2020 Research and Innovation Program under grant agreement no. 824110 (EASI-genomics). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (RECOVER WP 6). The Neurometabolic Diseases Laboratory received funding from the European Union’s Horizon 2020 Research and Innovation Program (EasiGenomics grant no. 824110 COVID-19/PID12342). A.P., R.P.d.D., C.R.-G., and C.F. were funded by Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación DISA (OA18/017), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The laboratories of G.N. and A.N. were supported by a grant awarded to Regione Lazio (PROGETTI DI GRUPPI DI RICERCA 2020) no. A0375-2020-36663, GecoBiomark. A. Amara’s laboratory was supported by ANR under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the FRM (EQU202003010193), ANR (ANR-20-COVI-000 project IDISCOVR and ANR-20-CO11-0004 project FISHBP), and the University of Paris (Plan de Soutien Covid-19: RACPL20FIR01-COVID-SOUL). This work was supported, in part, by the Division of Intramural Research, NIAID, NIH (grants 1ZIAAI001265 to H.C.S. and ZIA AI001270 to L.D.N.). The G.C. laboratory was supported by the Italian Ministry of Health (grant COVID-2020-12371617) and the intramural COVID Host Genetics program. The J.L.F. laboratory was supported, in part, by the Coopération Scientifique France-Colciencias (ECOS-Nord/COLCIENCIAS/MEN/ICETEX; 806-2018) and Colciencias contract 713-2016 (no. 111574455633). The V.S. laboratory was supported by ANR DENDRISEPSIS (ANR-17-CE15-0003) and ANR APCOD (ANR-17-CE15-0003-01), a Fast Grant from the Mercatus Center, FRM, University of Paris PLAN D’URGENCE COVID19. The N.M. laboratory was supported by Sidra Medicine (SDR400048) and the Qatar National Research Fund (grant No. NPRP9-251-3-045)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

  • Zhang, Qian
  • Dorgham, Karim
  • Schlüter, Agatha
  • Quiros Roldan, Eugenia
  • Novelli, Giuseppe
  • Planas Serra, Laura
  • Rodríguez Palmero, Agustí
  • COVID-STORM Clinicians
  • COVID Clinicians
  • Imagine COVID Group
  • French COVID Cohort Study Group
  • CoV-Contact Cohort
  • Amsterdam UMC Covid-19 Biobank
  • COVID Human Genetic Effort
  • NIAID-USUHS/TAGC COVID Immunity Group
Clinical outcome upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ranges from silent infection to lethal coronavirus disease 2019 (COVID-19). We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern Toll-like receptor 3 (TLR3)- and interferon regulatory factor 7 (IRF7)-dependent type I interferon (IFN) immunity to influenza virus in 659 patients with life-threatening COVID-19 pneumonia relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally defined LOF variants underlying autosomal-recessive or autosomal-dominant deficiencies in 23 patients (3.5%) 17 to 77 years of age. We show that human fibroblasts with mutations affecting this circuit are vulnerable to SARS-CoV-2. Inborn errors of TLR3-and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

  • Matuozzo, Daniela
  • Gut, Marta
  • Cobat, Aurélie
Background: We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15-20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases. Methods: We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded. Results: No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5-528.7, P = 1.1 × 10-4) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3-8.2], P = 2.1 × 10-4). This enrichment was further strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model (OR = 19.65[95%CI 2.1-2635.4], P = 3.4 × 10-3), and (2) considering as pLOF branchpoint variants with potentially strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3-8.4], P = 7.7 × 10-8). Finally, the patients with pLOF/bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients (56.0 [17.3] years; P = 1.68 × 10-5). Conclusions: Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old. Trial registration: ClinicalTrials.gov NCT04262921 NCT04259892 NCT04352348., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program COVIFERON (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the Square Foundation, Grandir—Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 10101616. P Bastard was supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). The French COVID Cohort study group was sponsored by INSERM and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20–0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, and the European Commission (Grant RECOVER WP 6). The COVIDeF study was supported by the French Ministry of Health, Fondation AP-HP et Programme Hospitalier de Recherche Clinique (PHRC COVID-19–20-0048) and was sponsored by APHP. Y.Z., O.M.D., L.D.N., H.C.S. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. G.N. and A.N. are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020–36663, GecoBiomark. I Meyts is a Senior Clinical Investigator at the Research Foundation – Flanders, and is supported by the CSL Behring Chair of Primary Immunodeficiencies, by the KU Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by the FWO Grants G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959). This work is supported by the Swiss National Science Foundation (grant # 310030L_197721 to JF). This work is supported by ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, and COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017–6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grant AJF202059 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I Erkizia, E Grau, M Massanella, and J Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling and processing.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A method for multiplexed full-length single-molecule sequencing of the human mitochondrial genome

  • Keraite, Ieva
  • Becker, Philipp
  • Canevazzi, Davide
  • Frias-López, Cristina
  • Dabad, Marc
  • Tonda, Raúl
  • Paramonov, Ida
  • Ingham, Matthew
  • Brun-Heath, Isabelle
  • Leno, Jordi
  • Abulí, Anna
  • García-Arumí, Elena
  • Heath, Simon
  • Gut, Marta
  • Gut, Ivo Glynne
Methods to reconstruct the mitochondrial DNA (mtDNA) sequence using short-read sequencing come with an inherent bias due to amplification and mapping. They can fail to determine the phase of variants, to capture multiple deletions and to cover the mitochondrial genome evenly. Here we describe a method to target, multiplex and sequence at high coverage full-length human mitochondrial genomes as native single-molecules, utilizing the RNA-guided DNA endonuclease Cas9. Combining Cas9 induced breaks, that define the mtDNA beginning and end of the sequencing reads, as barcodes, we achieve high demultiplexing specificity and delineation of the full-length of the mtDNA, regardless of the structural variant pattern. The long-read sequencing data is analysed with a pipeline where our custom-developed software, baldur, efficiently detects single nucleotide heteroplasmy to below 1%, physically determines phase and can accurately disentangle complex deletions. Our workflow is a tool for studying mtDNA variation and will accelerate mitochondrial research., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 – EASI-Genomics (I.G.G.) and the ERC Synergy project BCLL@las under grant agreement No 810287 (I.G.G.). Institutional support was from the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias and cofunded with ERDF funds (PI19/01772). We acknowledge the institutional support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and institutional co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme to the institute.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The European Genome-phenome Archive in 2021

  • Freeberg, Mallory Ann
  • Fromont, Lauren A.
  • D&apos;Altri, Teresa, 1984-
  • Jene, Aina
  • Moldes, Mauricio
  • Ariosa, Roberto
  • Fernández-Orth, Dietmar
  • Haziza, Frédéric
  • Martinez Llobet, Oscar
  • Milla, Gemma
  • Rueda, Manuel
  • Singh, Babita, 1986-
  • Torre, Sabela de la
  • Uyan, Umuthan
  • Vasallo, Claudia
  • Guigó Serra, Roderic
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Rambla de Argila, Jordi
The European Genome-phenome Archive (EGA - https://ega-archive.org/) is a resource for long term secure archiving of all types of potentially identifiable genetic, phenotypic, and clinical data resulting from biomedical research projects. Its mission is to foster hosted data reuse, enable reproducibility, and accelerate biomedical and translational research in line with the FAIR principles. Launched in 2008, the EGA has grown quickly, currently archiving over 4,500 studies from nearly one thousand institutions. The EGA operates a distributed data access model in which requests are made to the data controller, not to the EGA, therefore, the submitter keeps control on who has access to the data and under which conditions. Given the size and value of data hosted, the EGA is constantly improving its value chain, that is, how the EGA can contribute to enhancing the value of human health data by facilitating its submission, discovery, access, and distribution, as well as leading the design and implementation of standards and methods necessary to deliver the value chain. The EGA has become a key GA4GH Driver Project, leading multiple development efforts and implementing new standards and tools, and has been appointed as an ELIXIR Core Data Resource., Horizon 2020 Programme of the European Union [CORBEL [654248], ELIXIR-EXCELERATE [676559], Solve-RD [779257], EASI-Genomics [824110], EJP-RD [825575], CINECA [825775], EuCanCan [825835], EUCanshare [825903], ELIXIR-CONVERGE [871075]]; Wellcome Trust Global Alliance for Genomics and Health [201535/Z/16/Z]; UK Biobank; Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation [2017-171304 (5022)]; European Molecular Biology Laboratory (EMBL); LaCaixa Foundation [004745/008034]; [LCF/PR/CE20/50740008]. Funding for open access charge: LaCaixa Foundation [LCF/PR/CE20/50740008].
Docta Complutense
Publication Artículo científico (JournalArticle)

A memory transcriptome time course reveals essential long-term memory transcription factors

  • Jones, Spencer G.
  • Gil Martí, Beatriz
  • Sacristán Horcajada, Eva
  • Edison, Abigail C.
  • Butler, Emily F.
  • Miandashti, Neda
  • Roselli, Camilla
  • Turiégano, Enrique
  • Boto, Tamara
  • Kramer, Jamie M.
  • Martín Castro, Francisco Antonio
Long-term memory (LTM) requires transcription and translation of new proteins, yet the transcriptional control of memory remains poorly understood. Here, we performed a transcriptome time-course during LTM formation in Drosophila melanogaster exposed to courtship conditioning. We identified a mushroom body-specific transcriptional memory trace that becomes activated during memory consolidation. Using scRNAseq of CREB-activated cells we were able to detect a persistent transcriptional response in MB neurons after LTM consolidation and retrieval. As a proof of causality, we conducted a loss-of-function screen for genes comprising the transcriptional memory trace, finding 16 positive hits whose disruption impaired LTM. Among them, we identified two neuron activity-regulated genes, Hr38 and sr, which encode transcription factors that are activated by courtship LTM training, required for LTM, and bind to many genes comprising the transcriptional memory trace. Overall, we further define the transcriptional response to LTM and identify transcription factors that may help shape it.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer

  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Ensenyat Méndez, Miquel|||0000-0003-4192-806X
  • Orozco, Javier I. J|||0000-0003-2585-358X
  • Íñiguez-Muñoz, Sandra|||0000-0003-4916-1457
  • Valdez, Betsy
  • Wang, Chuan
  • Mezger, Anja|||0000-0002-7337-9547
  • Choi, Eunkyoung
  • Tran, Yan Zhou
  • Yao, Liqun
  • Bonath, Franziska
  • Olsen, Remi-André
  • Ormestad, Mattias
  • Esteller, M|||0000-0003-4490-6093
  • Lupien, Mathieu|||0000-0003-0929-9478
  • Marzese, Diego|||0000-0002-3258-8852
Objectives: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited treatment options. Unlike other breast cancer subtypes, the scarcity of specific therapies and greater frequencies of distant metastases contribute to its aggressiveness. We aimed to find epigenetic changes that aid in the understanding of the dissemination process of these cancers. Data description: Using CRISPR/Cas9, our experimental approach led us to identify and disrupt an insulator element, IE8, whose activity seemed relevant for cell invasion. The experiments were performed in two well-established TNBC cellular models, the MDA-MB-231 and the MDA-MB-436. To gain insights into the underlying molecular mechanisms of TNBC invasion ability, we generated and characterized high-resolution chromatin interaction (Hi-C) and chromatin accessibility (ATAC-seq) maps in both cell models and complemented these datasets with gene expression profiling (RNA-seq) in MDA-MB-231, the cell line that showed more significant changes in chromatin accessibility. Altogether, our data provide a comprehensive resource for understanding the spatial organization of the genome in TNBC cells, which may contribute to accelerating the discovery of TNBC-specific alterations triggering advances for this devastating disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors

  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Ensenyat Méndez, Miquel|||0000-0003-4192-806X
  • Íñiguez-Muñoz, Sandra|||0000-0003-4916-1457
  • Orozco, Javier I. J.|||0000-0003-2585-358X
  • Valdez, Betsy
  • Salomon, Matthew P.
  • Matsuba, Chikako
  • Solivellas-Pieras, Maria
  • Bedoya-López, Andrés F.
  • Sesé, Borja
  • Mezger, Anja|||0000-0002-7337-9547
  • Ormestad, Mattias
  • Unzueta, Fernando
  • Strand, Siri Hundtofte
  • Boiko, Alexander D.
  • Hwang, Eun Shelley
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • DiNome, Maggie L.|||0000-0002-1926-292X
  • Esteller, M.|||0000-0003-4490-6093
  • Lupien, Mathieu|||0000-0003-0929-9478
  • Marzese, Diego|||0000-0002-3258-8852
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matrix metalloprotease (MMP) dysregulation impacting tumor invasion, which is the first step of the metastatic process. Methods: We combined RNA expression and chromatin interaction data to identify insulator elements potentially associated with MMP gene expression and invasion. We employed CRISPR/Cas9 to disrupt the CCCTC-Binding Factor (CTCF) binding site on an insulator element downstream of the MMP8 gene (IE8) in two TNBC cellular models. We characterized these models by combining Hi-C, ATAC-seq, and RNA-seq with functional experiments to determine invasive ability. The potential of our findings to predict the progression of ductal carcinoma in situ (DCIS), was tested in data from clinical specimens. Results: We explored the clinical relevance of an insulator element located within the Chr11q22.2 locus, downstream of the MMP8 gene (IE8). This regulatory element resulted in a topologically associating domain (TAD) boundary that isolated nine MMP genes into two anti-correlated expression clusters. This expression pattern was associated with worse relapse-free (HR = 1.57 [1.06 - 2.33]; p = 0.023) and overall (HR = 2.65 [1.31 - 5.37], p = 0.005) survival of TNBC patients. After CRISPR/Cas9-mediated disruption of IE8, cancer cells showed a switch in the MMP expression signature, specifically downregulating the pro-invasive MMP1 gene and upregulating the antitumorigenic MMP8 gene, resulting in reduced invasive ability and collagen degradation. We observed that the MMP expression pattern predicts DCIS that eventually progresses into invasive ductal carcinomas (AUC = 0.77, p < 0.01). Conclusion: Our study demonstrates how the activation of an IE near the MMP8 gene determines the regional transcriptional regulation of MMP genes with opposing functional activity, ultimately influencing the invasive properties of aggressive forms of breast cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years and account for ~ 20% of COVID-19 deaths

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, Adrian|||0000-0002-1083-5787
  • Le Voyer, Tom|||0000-0002-7253-3135
  • Rosain, Jérémie|||0000-0002-2822-161X
  • Philippot, Quentin
  • Manry, Jeremy|||0000-0001-5998-2051
  • Michailidis, Eleftherios|||0000-0002-9907-4346
  • Hoffmann, Hans-Heinrich|||0000-0003-0554-0244
  • Eto, Shohei|||0000-0002-2885-7490
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Bizien, Lucy|||0000-0001-9163-9122
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Yang, Rui|||0000-0003-4427-2158
  • Haljasmägi, Liis|||0000-0001-7162-9808
  • Migaud, Mélanie|||0000-0003-3062-1214
  • Särekannu, Karita|||0000-0002-5984-668X
  • Maslovskaja, Julia
  • de Prost, Nicolas|||0000-0002-4833-4320
  • Tandjaoui-Lambiotte redondo, Yacine|||0000-0003-1123-4788
  • Luyt, Charles-Edouard|||0000-0001-7424-2705
  • Amador Borrero, Blanca|||0000-0001-6170-8721
  • Gaudet, Alexandre
  • Poissy, Julien|||0000-0001-6017-5353
  • Morel, Pascal
  • Richard, Pascale|||0000-0003-1864-3824
  • Cognasse, Fabrice|||0000-0001-8041-928X
  • Troya, Jesús|||0000-0001-7323-114X
  • Trouillet-Assant, Sophie|||0000-0001-6439-4705
  • Belot, Alexandre|||0000-0003-4902-5332
  • Saker, Kahina|||0000-0001-8825-5400
  • Garçon, Pierre
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Lagier, Jean-Christophe
  • Gentile, Stéphanie|||0000-0003-3858-9503
  • Rosen, Lindsey|||0000-0001-5894-3878
  • Shaw, Elana|||0000-0001-9265-8026
  • Morio, Tomohiro
  • Tanaka, Junko
  • Dalmau, David|||0000-0003-1936-478X
  • Tharaux, Pierre-Louis|||0000-0002-6062-5905
  • Sene, Damien
  • Stepanian, Alain|||0000-0002-2942-0901
  • Mégarbane, Bruno|||0000-0002-2522-2764
  • Triantafyllia, Vasiliki|||0000-0001-5832-4014
  • Fekkar, Arnaud|||0000-0001-9954-075X
  • Heath, James R.|||0000-0001-5356-4385
  • Franco, Jose|||0000-0001-5664-6415
  • Anaya, Juan-Manuel|||0000-0002-6444-1249
  • Solé-Violán, Jordi
  • Imberti, Luisa|||0000-0002-2075-8391
  • Biondi, Andrea
  • Bonfanti, Paolo|||0000-0001-7289-8823
  • Castagnoli, Riccardo|||0000-0003-0029-9383
  • Delmonte, Ottavia M.
  • Zhang, Yu|||0000-0002-0332-0013
  • Snow, Andrew|||0000-0002-8728-6691
  • Holland, Steven|||0000-0003-3207-5464
  • Biggs, Catherine|||0000-0002-4363-2660
  • Moncada-Velez, Marcela|||0000-0002-3073-5345
  • Arias, Andrés Augusto|||0000-0002-9478-8403
  • Lorenzo, Lazaro|||0000-0001-6648-8684
  • Boucherit, Soraya|||0000-0002-8819-7594
  • Coulibaly, Boubacar
  • Anglicheau, Dany|||0000-0001-5793-6174
  • Planas, Anna Maria|||0000-0002-6147-1880
  • Haerynck, Filomeen|||0000-0001-9161-7361
  • Duvlis, Sotirija|||0000-0001-8587-7386
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, Sevgi|||0000-0001-7344-8947
  • Bousfiha, Ahmed Aziz|||0000-0002-5011-9873
  • El Bakkouri, Jalila|||0000-0003-2303-3369
  • Ramirez-Santana, Carolina|||0000-0003-2137-4899
  • Paul, Stephane|||0000-0002-8830-4273
  • Pan-Hammarström, Qiang|||0000-0003-1990-8804
  • Hammarström, Lennart|||0000-0002-8635-9609
  • Dupont, Annabelle|||0000-0002-1554-9931
  • Kurolap, Alina|||0000-0002-7005-3621
  • Metz, Christine N.|||0000-0002-1013-1691
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Casari, Giorgio|||0000-0002-0115-8980
  • Lampasona, Vito|||0000-0001-5162-8445
  • Ciceri, Fabio|||0000-0003-0873-0123
  • Barreiros, Lucila|||0000-0002-9818-2345
  • Domínguez-Garrido, Elena|||0000-0002-2066-0511
  • Vidigal, Mateus de Castro|||0000-0002-8895-652X
  • Zatz, Mayana|||0000-0003-3970-8025
  • van de Beek, Diederik|||0000-0002-4571-044X
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Stepanovskyy, Yuriy|||0000-0001-6339-5490
  • Boyarchuk, Oksana|||0000-0002-1234-0040
  • Nukui, Yoko|||0000-0002-6123-5212
  • Tsumura, Miyuki
  • Vidaur, Loreto|||0000-0002-6720-4900
  • Tangye, Stuart|||0000-0002-5360-5180
  • Burrel, Sonia|||0000-0002-7783-2601
  • Duffy, Darragh|||0000-0002-8875-2308
  • Quintana-Murci, Lluis|||0000-0003-2429-6320
  • Klocperk, Adam
  • Kann, Nelli Y.|||0000-0003-3564-6496
  • Shcherbina, Anna|||0000-0002-3113-4939
  • Lau, Yu Lung|||0000-0002-4780-0289
  • Leung, Daniel|||0000-0002-9360-6233
  • Coulongeat, Matthieu|||0000-0003-1986-3546
  • Marlet, Julien|||0000-0002-8645-8703
  • Koning, Rutger|||0000-0003-3128-5072
  • Reyes, Luis Felipe|||0000-0003-1172-6539
  • Chauvineau-Grenier, Angélique
  • Venet, Fabienne|||0000-0003-0462-4235
  • Monneret, Guillaume|||0000-0002-9961-5739
  • Nussenzweig, Michel|||0000-0003-0592-8564
  • Arrestier, Romain
  • Boudhabhay, Idris
  • Baris-Feldman, Hagit|||0000-0003-4065-7560
  • Hagin, David|||0000-0003-2702-1031
  • Wauters, Joost|||0000-0002-5983-3897
  • Meyts, Isabelle|||0000-0003-1214-0302
  • Dyer, Adam|||0000-0003-1356-510X
  • Kennelly, Sean P.
  • Bourke, Nollaig|||0000-0003-4313-6859
  • Halwani, Rabih|||0000-0002-6516-7771
  • Sharif-Askari, Narjes Saheb|||0000-0003-0482-6777
  • Dorgham, Karim|||0000-0001-9539-3203
  • Sallette, Jérome
  • Sedkaoui, Souad Mehlal
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Morandeira Rego, Francisco|||0000-0002-6099-1040
  • Roussel, Lucie|||0000-0001-5355-702X
  • Vinh, Donald C.|||0000-0003-1347-7767
  • Ostrowski, Sisse Rye|||0000-0001-5288-3851
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Prando, Carolina|||0000-0002-9570-9770
  • Bonradenko, Anastasiia
  • Spaan, András|||0000-0001-5981-7259
  • Gilardin, Laurent|||0000-0001-9212-0859
  • Fellay, Jacques|||0000-0002-8240-939X
  • Lyonnet, Stanislas
  • Bilguvar, Kaya|||0000-0002-7313-7652
  • Lifton, Richard P.
  • Mane, Shrikant|||0000-0002-3267-5139
  • Anderson, Mark|||0000-0002-3093-4758
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, Vivien|||0000-0002-4020-824X
  • Zhang, Shen-Ying|||0000-0002-9449-3672
  • Vandreakos, Evangelos|||0000-0001-5536-1661
  • Hermine, Olivier|||0000-0003-2574-3874
  • Pujol, Aurora|||0000-0002-9606-0600
  • Peterson, Pärt|||0000-0001-6755-791X
  • Mogensen, Trine Hyrup|||0000-0002-1853-9704
  • Rowen, Lee
  • Mond, James
  • Debette, Stéphanie|||0000-0001-8675-7968
  • De Lamballerie, Xavier|||0000-0001-7895-2720
  • Duval, Xavier
  • Mentré, France
  • Zins, Marie|||0000-0002-4540-4282
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Gorochov, Guy|||0000-0003-2097-9677
  • Solanich, Xavier|||0000-0002-2572-2187
  • Susen, Sophie|||0000-0001-5953-163X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Raoult, Didier
  • Vasse, Marc
  • Gregersen, Peter K.|||0000-0003-1613-1518
  • Piemonti, Lorenzo|||0000-0002-2172-2198
  • Rodríguez-Gallego, Carlos|||0000-0002-4344-8644
  • Notarangelo, Luigi|||0000-0002-8335-0262
  • Su, Helen C.|||0000-0002-5582-9110
  • Kisand, Kai|||0000-0002-5426-4648
  • Okada, Satoshi|||0000-0002-4622-5657
  • Puel, Anne|||0000-0003-2603-0323
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Rice, Charles M.|||0000-0003-3087-8079
  • Tiberghien, Pierre|||0000-0002-9310-8322
  • Zhang, Qian|||0000-0002-9040-3289
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Abel, Laurent|||0000-0001-7016-6493
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology

  • Stanley, Kate
  • Jatsenko, Tatjana
  • Tuveri, Stefania
  • Sudhakaran, Dhanya
  • Lannoo, Lore
  • Van Calsteren, Kristel
  • Toledo, Rodrigo
Cell-free DNA fragmentation; Cancer, Fragmentación de ADN libre de células; Cáncer, Fragmentació d'ADN lliure de cèl·lules; Càncer, Circulating cell-free DNA (cfDNA) fragments have characteristics that are specific to the cell types that release them. Current methods for cfDNA deconvolution typically use disease tailored marker selection in a limited number of bulk tissues or cell lines. Here, we utilize single cell transcriptome data as a comprehensive cellular reference set for disease-agnostic cfDNA cell-of-origin analysis. We correlate cfDNA-inferred nucleosome spacing with gene expression to rank the relative contribution of over 490 cell types to plasma cfDNA. In 744 healthy individuals and patients, we uncover cell type signatures in support of emerging disease paradigms in oncology and prenatal care. We train predictive models that can differentiate patients with colorectal cancer (84.7%), early-stage breast cancer (90.1%), multiple myeloma (AUC 95.0%), and preeclampsia (88.3%) from matched controls. Importantly, our approach performs well in ultra-low coverage cfDNA datasets and can be readily transferred to diverse clinical settings for the expansion of liquid biopsy., We would like to thank the patients and their families for agreeing to participate in this study. We would like to thank the Genomics Core at KU Leuven for the use of the sequencing facilities. Funding was received from the European Union’s Horizon 2020 research and innovation program under grant agreement No 824110 – EASI-Genomics (J.R.V.) and the Marie Skłodowska-Curie grant agreement No 813707 (MATER), from Kom Op Tegen Kanker (Stand up to Cancer) KOTK/2018/11468, from the Flemish cancer society (2016/10728/2603 to A.C.), and FWO-SBO grant S003422N, and from Agentschap Innoveren en Ondernemen (VLAIO; Flanders Innovation & Entrepreneurship grant HBC.2018.2108). S.T. was supported by FWO SB/1S74420N. Institutional support was received from the KU Leuven, C1- C14/18/092, C14/22/125, and C3/20/100 to J.R.V
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A method for multiplexed full-length single-molecule sequencing of the human mitochondrial genome

  • Keraite, Ieva
  • Becker, Philipp
  • Canevazzi, Davide
  • Frías-López, Cristina
  • Dabad, Marc
  • Leno Colorado, Jorge
  • Abulí Vidal, Anna
  • García Arumí, Elena
  • Tonda, Raul
Data processing; DNA sequencing; Genomic analysis, Tratamiento de datos; Secuenciación de ADN; Análisis genómico, Tractament de dades; Seqüenciació d'ADN; Anàlisi genòmica, Methods to reconstruct the mitochondrial DNA (mtDNA) sequence using short-read sequencing come with an inherent bias due to amplification and mapping. They can fail to determine the phase of variants, to capture multiple deletions and to cover the mitochondrial genome evenly. Here we describe a method to target, multiplex and sequence at high coverage full-length human mitochondrial genomes as native single-molecules, utilizing the RNA-guided DNA endonuclease Cas9. Combining Cas9 induced breaks, that define the mtDNA beginning and end of the sequencing reads, as barcodes, we achieve high demultiplexing specificity and delineation of the full-length of the mtDNA, regardless of the structural variant pattern. The long-read sequencing data is analysed with a pipeline where our custom-developed software, baldur, efficiently detects single nucleotide heteroplasmy to below 1%, physically determines phase and can accurately disentangle complex deletions. Our workflow is a tool for studying mtDNA variation and will accelerate mitochondrial research., This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 – EASI-Genomics (I.G.G.) and the ERC Synergy project BCLL@las under grant agreement No 810287 (I.G.G.). Institutional support was from the Spanish Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias and cofunded with ERDF funds (PI19/01772). We acknowledge the institutional support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and institutional co-financing with the European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d’Empresa i Coneixement and the CERCA Programme to the institute.